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ABSTRACT 
 
 
Since the discovery of HIV-1, the production of an effective prophylactic or 
therapeutic vaccine remains elusive. An effective vaccine must be able to elicit a 
potent humoral and cellular immune response. Neutralizing antibodies target the 
envelope glycoproteins on the surface of HIV-1 virions thereby preventing viral 
entry.  Unfortunately, to date only a handful of neutralizing antibodies have been 
identified that are capable of neutralizing different viral strains within diverse 
subtypes, and none have been isolated from HIV-1 subtype C infected patients. In 
this study, we screened four different HIV-1 subtype C infected patient cohorts for 
the presence of neutralizing antibodies against a panel of 5 subtype C and 1 
subtype B pseudovirus/es in a pseudovirion based neutralizing antibody assay. 
The CT cohort comprised 9 slow progressor plasma samples, the FV cohort 
consisted of 11 antiretroviral drug naïve HIV-1 subtype C infected plasma 
samples. Plasma samples from 10 antiretroviral treatment experienced HIV-1 
subtype C infected patients failing first line therapy made up the DR cohort and the 
JM cohort consisted of 10 serum samples from HIV-1 seropositive or seronegative 
individuals with an autoimmune disorder. A pseudovirion neutralizing antibody 
assay was successfully established, and all plasma and serum samples were heat 
inactivated and screened using this assay. Analysis of the percentage 
neutralization and IC50 data showed no correlation between the presence of 
neutralizing antibodies and delayed disease progression in the SP cohort. High 
levels of neutralizing antibodies were observed in the DR cohort, however future 
studies are required to confirm if the measured neutralization is due to residual 
antiretroviral drugs in the plasma or neutralizing antibodies. No samples within the 
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FV cohort showed promising neutralizing antibody activity however the JM cohort 
harboured 3 serum samples (TN5, TN6 and TN8) that exhibited a greater than 
average breadth of neutralization and are worth investigating further in future 
studies. Patients TN5, TN6 and TN8 were all HIV-1 positive with an additional 
autoimmune disease. The availability of stored bone marrow samples for TN5, 
TN6 and TN8 will allow for the generation of antibody phage display libraries and 
isolation of monoclonal antibodies, with potentially broadly cross reactive activity.        
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CHAPTER 1: INTRODUCTION 
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1.1. Human immunodeficiency virus (HIV) and Acquired immunodeficiency 
syndrome (AIDS) 
 
1.1.1 HIV and the global AIDS pandemic 
 
AIDS was first identified in humans in 1981 and is defined as a condition 
characterized by severe immune suppression followed by a decline in CD4+ T-
lymphocytes as well as the emergence of opportunistic infections such as 
tuberculosis or illnesses such as Kaposi’s sarcoma (UNAIDS 2010). Since the 
reports of the first AIDS cases, the number of deaths among individuals with AIDS 
has rapidly escalated. In the 1980’s AIDS was most prevalent among homosexual 
men and injection drug users and heterosexual contact accounted for the minority 
of infected individuals (CDC 1981). By contrast, the incidence of AIDS among 
individuals exposed through heterosexual contact has increased substantially 
(UNAIDS 2010).    
 
The causal agent of AIDS was initially believed to belong to the family of human T-
lymphotropic retroviruses (HTLV) but differed biologically and morphologically from 
previous isolates, HTLV-I and HTLV-II (Barre-Sinoussi, Chermann et al. 1983; 
Gallo, Salahuddin et al. 1984). Eventually in 1986, the retrovirus was named HIV 
(Coffin, Haase et al. 1986). 
 
HIV and AIDS-related illnesses remain one of the leading causes of death 
worldwide with Southern Africa being the most heavily affected by this epidemic, 
where more than 10% of the population is infected with HIV (UNAIDS 2010) 
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(Figure 1.1). In 2009, there were 2.6 million new infections and 1.8 million AIDS-
related deaths reported globally (UNAIDS 2010). In Sub Saharan Africa alone, 1.3 
million AIDS-related deaths were reported in 2009 with 1.8 million new infections 
reported among adults and children (UNAIDS 2010). Although the rate of newly 
acquired HIV infections in Sub Saharan Africa has decreased from 2008 (2.7 
million), the total number of individuals living with HIV continues to rise where 
poverty, limited access to good health care systems and poor education fuels the 
spread of the virus (UNAIDS 2010). The situation continues to deteriorate by the 
lack of an effective HIV vaccine. Therefore there is an urgent need for the 
development of a prophylactic or therapeutic vaccine. 
 
1.1.2 HIV Classification 
 
HIV can be divided into 2 types, HIV-1 and HIV-2 (Clavel, Guetard et al. 1986; 
Coffin, Haase et al. 1986). HIV-1 can be categorized into four phylogenetic groups. 
Group M, group O, group N and the recently identified group P (Simon, Mauclere 
et al. 1998; Plantier, Leoz et al. 2009). Group M is responsible for the worldwide 
HIV-1 epidemic and can be further divided into 9 subtypes (A, B, C, D, F, G, H, J 
and K) as well as combinations of one or more subtypes known as circulating 
recombinant forms (CRF) (Robertson, Anderson et al. 2000). 
 
HIV-2 became evident in a Sengalese woman in 1985 (Barin, M'Boup et al. 1985). 
Phylogenetic analysis shows that HIV-2 is closely related to Simian 
Immunodeficiency virus (SIV) from the sooty mangabey monkey native to West 
Africa, whereas HIV-1 appears to be closely related to viruses found in 
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chimpanzees (Chen, Luckay et al. 1997). HIV-2 can be divided into 7 different 
groups (A, B, C, D, E, F and G) (Chen, Luckay et al. 1997; Yamaguchi, Devare et 
al. 2000; Damond, Worobey et al. 2004).  
 
 
 
Figure 1.1: World map showing the prevalence of HIV-1 infection in adults across 
the globe. The total population of individuals living with HIV-1 within different parts 
of the world is indicated by the colour coded key. Figure copied from the 2010 
report on the global AIDS epidemic (UNAIDS 2010).  
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1.1.3 HIV-1 structure and genome organization  
 
HIV-1 is a lentivirus belonging to the retroviridae family. A common feature of all 
retroviruses is that they synthesize DNA from their RNA genome via the error 
prone reverse transcriptase enzyme (Leis, Baltimore et al. 1988). The mature HIV-
1 virion has a spherical shape and is approximately 100nm in diameter 
(Gelderblom, Özel et al. 1988). The virion is composed of two identical copies of 
plus-strand RNA together with the error-prone reverse transcriptase (RT), 
integrase (IN), RNase H and protease (PR) enzymes encapsulated within the viral 
core (CA; p24), which is enclosed within the matrix (MA; p17) (Leis, Baltimore et 
al. 1988) (Figure 1.2). The envelope precursor (gp160) is cleaved by host 
proteases to generate the surface glycoprotein, gp120 and the transmembrane 
glycoprotein, gp41 (Pinter, Honnen et al. 1989). Three identical copies of gp120 
are non-covalently linked to three identical gp41 molecules, forming the functional 
Env trimer, arranged as spikes on the HIV-1 virion (Leis, Baltimore et al. 1988) 
(Figure1.2). 
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gp120
gp41
Lipid membrane
Matrix
Capsid
RNA
Reverse transcriptase
 
 
Figure 1.2: Schematic diagram of a mature HIV-1 virion. The envelope 
glycoprotein spikes, composed of gp120 (purple) and gp41 (green) are embedded 
in a host derived lipid membrane (grey). Two identical copies of plus strand RNA 
and reverse transcriptase is shown in yellow and red respectively, enclosed within 
the viral capsid (green). The viral capsid is enclosed within the matrix (blue). 
 
The complex HIV-1 genome (9.8kb) contains only nine genes which can be 
categorized into 4 accessory genes, 2 regulatory genes and 3 structural genes, 
flanked by two identical long terminal repeat (LTR) regions (Leis, Baltimore et al. 
1988). Vpu, vpr, vif and nef comprise the accessory genes of HIV-1 
(Subbramanian and Cohen 1994). Vpu  functions to downregulate CD4 receptor 
expression via ubiquitin-mediated degradation to promote the extracellular release 
of viral particles (Terwilliger, Cohen et al. 1989; Chen, Maldarelli et al. 1993) and 
Vpr is involved in the translocation of the pre-integration complex (PIC) from the 
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cytoplasm into the nucleus (Heinzinger, Bukinsky et al. 1994). Vif is essential for 
viral maturation as well as infectivity and interacts with the host-specific factor, 
apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G 
(APOBEC3G) and inhibits the antiviral properties of APOBEC3G (Stopak, de 
Noronha et al. 2003). Nef functions to downregulate CD4 expression by interacting 
with cellular proteins involved in signal transduction to alter T-cell receptor 
signalling (Aiken, Konner et al. 1994; Miller, Warmerdam et al. 1994). 
 
Regulatory genes include tat and rev. Tat functions to increase the transcription of 
HIV-1 genes (Jeang 1994; Leitner, Foley et al. 2005) and Rev is involved in the 
export of unspliced and single spliced mRNA from the nucleus to the cytoplasm 
(Feinberg, Jarrett et al. 1986; Nekhai and Jeang 2006). Gag, pol and env comprise 
the structural genes of HIV-1. The Gag precursor (assemblin) is processed by 
HIV-1 protease (PR) into the viral capsid (CA), matrix (MA) and nucleocapsid (NC) 
proteins (Freed 1998) (Figure 1.2). The pol gene encodes the viral enzymes; 
protease (PR), reverse transcriptase (RT), RNAse H and integrase (IN), which are 
essential for viral integration into the host genome, (Jacks, Power et al. 1988; Leis, 
Baltimore et al. 1988) (Figure 1.3). The env gene encodes the viral envelope 
glycoprotein, synthesized as a single polyprotein, gp160 in the endoplasmic 
reticulum. Post-gp160 synthesis, the polyprotein is heavily glycosylated in the 
Golgi complex before host proteases cleave it into the surface glycoprotein, gp120 
and the transmembrane glycoprotein, gp41 (Leis, Baltimore et al. 1988). The 
gp120 functions to recognise the host receptor and chemokine co-receptor, CD4 
and CCR5/CXCR4 respectively (Moore, Trkola et al. 1997). On the other hand, 
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gp41 functions in viral-host membrane fusion interactions (Wyatt and Sodroski 
1998).   
 
3’LTR
gag
Pol
Vif
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Tat
Vpr
Env/gp160
gp120 gp41
Post translational processing
gp41
Fusion domain Transmembrane domain
C1 V1    V2  C2   V3    C3   V4   C4   V5    C5
Vpu
5’LTR
 
 
Figure 1.3: Schematic diagram of HIV-1 genome organization. The gp120 
conserved and variable genes, C1-C5 and V1-V5, respectively are illustrated as 
well as the fusion and transmembrane domains of gp41.  
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1.2. HIV-1 Life cycle 
 
1.2.1 Overview of viral entry  
 
HIV entry into host target cells is initiated by the interaction between the gp120 
and the host receptor CD4 (Dalgleish, Beverley et al. 1984; Bour, Geleziunas et al. 
1995) (Figure 1.4, points 1). Post gp120-CD4 interaction, conformational changes 
in the gp120 expose the co-receptor binding site, allowing for the interaction 
between gp120 and its chemokine co-receptor, CCR5 or CXCR4 (Sattentau, 
Moore et al. 1993; Moore, Trkola et al. 1997). HIV strains which utilise CCR5 as 
the co-receptor are known as R5- or M-tropic viruses and strains utilizing CXCR4 
are referred to as X4- or T-tropic viruses. Strains of HIV exist with the ability to 
utilise both co-receptors and are known as dual tropic or R5X4 viruses (Moore, 
Trkola et al. 1997). 
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Figure 1.4: Schematic diagram of the HIV-1 life cycle. Viral life cycle steps are 
indicated by points 1 to 6. Figure copied from (Ramezani and Hawley 2002). 
 
Once gp120 interacts with its primary receptor and co-receptor, further 
conformational changes result in the shedding of gp120 from the virion (Hart, Kirsh 
et al. 1991), ultimately exposing the fusogenic domain of the gp41 as well as 
heptad repeat regions one and two (HR1 and HR2) of gp41 (Wyatt and Sodroski 
1998) (Figure 1.5A). Conformational changes in the transmembrane region of 
gp41 culminate in the insertion of HR1 into the host membrane. This subsequently 
results in the formation of a trimeric coiled coil structure known as the six helix 
bundle, where HR2 folds back on to HR1 in an anti-parallel manner bringing the 
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viral and host cell membranes closer together (Chan, Fass et al. 1997)  (Figure 
1.5B), thereby facilitating fusion and internalization.  
 
 
(A)  (B)  
 
Figure 1.5: (A) Schematic representation of the gp41 molecule exposing the HR1 
and HR2 regions shown in red and blue, respectively. Insertion of the HR1 region 
into the host cell membrane (grey) is illustrated. (B) Formation of the six helix 
bundle. The viral membrane is depicted in green and the host cell membrane is 
illustrated in grey. Figure copied from (Roche 2001).  
 
Once the virus has entered the target cell, its capsid is shed, releasing two copies 
of single plus-strand viral RNA, which is subsequently reverse transcribed into 
double stranded complementary DNA (cDNA) by the error-prone reverse 
transcriptase (Gelderblom 1991) (Figure 1.4, point 2). An HIV-1 pre integration 
complex (PIC) is then formed and contains viral integrase, reverse transcriptase, 
Vpr and matrix proteins (Farnet and Haseltine 1991). The PIC is responsible for 
the transport of the newly synthesized cDNA into the nucleus and integration of 
the cDNA into the host genome (Figure 1.4, point 3) where the transcription of viral 
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genes takes place together with host genes (Bukrinsky, Sharova et al. 1992) 
(Figure 1.4, point 4). The mRNA is then transported from the nucleus to the 
cytoplasm where translation of viral and host proteins occurs (Goto, Nakai et al. 
1998). RNA processing occurs, where double spliced RNA species translate into 
the viral proteins Tat and Rev, (Figure 1.4, point 5) and single spliced long length 
RNA is translated into Gag, Pol and Env (Goto, Nakai et al. 1998) (Figure 1.4, 
point 5). Host proteases cleave gp160 into the surface gp120 and transmembrane 
gp41 subunits (Wyatt and Sodroski 1998). The immature virions travel to the host 
membrane where they assemble and bud out of the cell taking part of the host lipid 
membrane (Figure 1.4, point 6). Viral protease continues to cleave long strands of 
protein (gag and pol) into smaller strands which are used to form mature viral 
particles that can initiate a new round of infection (Goto, Nakai et al. 1998) (Figure 
1.4, point 6).         
 
1.2.2. Host cellular proteins involved in the entry process 
 
1.2.2.1 The CD4 receptor 
 
The cluster of differentiation 4 (CD4) receptor molecule is a 58kDa T-cell 
transmembrane protein consisting of extracellular and transmembrane regions 
with a cytoplasmic tail at the C terminus (McDougal, Kennedy et al. 1986). The 
CD4 receptor is expressed on a subset of T-lymphocytes known as CD4+ T-cells 
and presents antigens to the major histocompatibility complex II molecule (MHC 
class II) found on the surface of antigen presenting cells (APC) to initiate an 
immune response (Germain 1997).   
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CD4 was first recognized as the primary cellular receptor used for HIV-1 entry in 
the 1980’s (Klatzmann, Barre-Sinoussi et al. 1984). Structural analysis of the CD4 
molecule has allowed for the identification of residues on CD4 that are involved in 
gp120 interactions (Ryu, Kwong et al. 1990) (Figure 1.6). It has been shown that 
the gp120 binding site on CD4 is situated in the N-terminus of the first extracellular 
domain of CD4 and involves a Phe43 residue which reaches into a hydrophobic 
cavity of gp120 (Sattentau, Arthos et al. 1989; Ryu, Kwong et al. 1990) (Figure 
1.6). 
 
 
Figure 1.6: Ribbon diagram of CD4 molecule in complex with HIV-1 gp120. 
 gp120 
 CD4 
Phe43 
residue 
involved in 
gp120-CD4 
interactions 
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The Ph43 residue is also depicted reaching into a recessed cavity of gp120. 
Figure adapted from (Kwong, Wyatt et al. 1998).  
 
1.2.2.2 Chemokine co-receptors CCR5 and CXCR4  
 
Chemokine receptors are defined as small molecules which mediate the 
chemotaxis of leukocytes (Yoshie, Imai et al. 1997). The α chemokine (CXC) 
receptor 4 (CXCR4) is normally expressed on the surface of haematopoietic cell 
types and is the receptor for the α-chemokine, stromal derived factor 1 (SDF-1) 
(Oberlin, Amara et al. 1996). The β chemokine (CC) receptor 5, CCR5 is 
commonly expressed on the surface of dendritic cells, T-cells and macrophages 
and binds to β-chemokines such as C-C motif chemokine ligand-5 (CCL5), C-C 
motif chemokine ligand-3 (CCL3) and C-C motif chemokine ligand-4 (CCL4), 
previously known as RANTES, MIP-1α and MIP-1β, respectively (Alkhatib, 
Combadiere et al. 1996). CCR5 and CXCR4 belong to the seven transmembrane-
spanning G protein-coupled receptors (Feng, Broder et al. 1996). HIV-1 strains 
which utilize CCR5 as their co-receptor are referred to as M-tropic viruses and 
strains which utilize CXCR4 for entry are known as T-tropic viruses (Moore, Trkola 
et al. 1997).  
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1.2.3 Viral proteins involved in the entry process 
 
1.2.3.1 gp120 
 
The gp120 is a conformationally flexible and heavily glycosylated protein 
consisting of five conserved regions (C1-C5), interspersed between five variable 
regions (V1-V5) (Modrow, Hahn et al. 1987) (Figure 1.3). The variable regions of 
gp120 play an essential role in viral infectivity, viral tropism and the shielding of 
neutralization epitopes. In particular the V3 loop (Figure 1.7) is involved in viral 
tropism but is well occluded from neutralizing antibody recognition and possesses 
diverse sequence variability (Ait-Khaled and Emery 1993). The conserved regions, 
C1 to C5 are vital for the interactions between gp120 and gp41 as well between 
gp120 and the primary CD4 receptor and co-receptor CCR5/CXCR4. On the 
native trimeric Env, the conserved regions are masked by the variable regions 
(Starcich, Hahn et al. 1986). Unfortunately, the variable regions of gp120 have a 
high degree of sequence diversity and subsequently present different Env 
epitopes to the immune system which allows for the continued viral immune 
escape from antibody recognition (Ait-Khaled and Emery 1993). The Env is also 
heavily glycosylated with poorly immunogenic glycans creating a glycan shield 
which can be rearranged without altering the functionality of the Env (Wyatt, 
Kwong et al. 1998). In addition, gp120 adopts a different conformation once bound 
to CD4, allowing for the exposure of the co-receptor binding site (Sullivan, Sun et 
al. 1998). Post gp120 co-receptor interactions, further conformational changes 
occur which requires large bonding energy to allow for the reordering of the gp120 
structure (Myszka, Sweet et al. 2000). The gp120 is subsequently shed from the 
virion, allowing the gp41 to facilitate viral fusion. The shed gp120 is extremely 
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immunogenic and acts as an immune decoy, exposing predominantly non 
neutralizing epitopes (Moore, Cao et al. 1994).  
 
Despite the many immune escape mechanisms employed by gp120, neutralizing 
antibody responses have been detected targeting conserved regions such as the 
CD4 binding site, the poorly immunogenic glycan shield on the surface of gp120, 
as well as co-receptor binding sites and variable regions of gp120. X-ray 
crystallography of gp120 has allowed for the identification of regions involved in 
CD4 and antibody binding, for example the X5 neutralizing antibody which targets 
the co-receptor binding site (Huang, Tang et al. 2005) (Figure 1.7). 
 
 
17 
 
Figure 1.7: Structure of the HIV-1 V3-containing gp120 core shown in red and 
grey bound to the CD4 receptor illustrated in yellow. The Fab portion of an anti-
gp120 antibody (X5) is indicated in light and dark blue. Figure copied from (Huang, 
Tang et al. 2005). 
 
1.2.3.2 gp41 
 
The gp41 transmembrane protein plays an essential role in viral fusion and 
consists of three domains; the ectodomain, transmembrane domain and the 
cytoplasmic tail (Chan, Fass et al. 1997). The ectodomain contains the membrane 
proximal external region (MPER), the fusion peptide as well as 2 hydrophobic 
regions, N-terminal heptad repeat (HR1) and C-terminal heptad repeat (HR2) 
which can self assemble in an anti parallel manner to form the six helix bundle, 
essential for viral fusion (Eckert, Malashkevich et al. 1998) (Figure 1.5). The gp41 
is anchored into the viral membrane via a tryptophan-rich transmembrane domain 
and the C terminal cytoplasmic tail (Gallaher, Ball et al. 1989). Antibody responses 
have been detected targeting the gp41 region; however most do not succeed at 
inhibiting viral entry and subsequent infection, due to viral escape mechanisms 
employed by HIV-1 to evade immune responses such as steric hindrance and the 
transient exposure of neutralizing epitopes (Purtscher, Trkola et al. 1994; Jiang, 
Lin et al. 1998; Zwick, Labrijn et al. 2001).  
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1.3. HIV-1 disease progression to AIDS 
 
HIV-1 undergoes a multiphasic disease progression which can be divided into 
primary infection, acute infection, chronic infection and AIDS (Figure 1.8). After 
transmission and successful infection, primary infection is characterized by a rapid 
decline in CD4+ T-cells together with a rapid increase in HIV-1 viral loads 
(Schnittman, Greenhouse et al. 1990). During acute infection, the virus is allowed 
to replicate uncontrollably to very high levels and a peak in viremia is observed 
(Little, McLean et al. 1999) (Figure 1.8). Cellular immune responses such as anti 
HIV-1 CD8+ cytotoxic T-lymphocytes are subsequently elicited , ultimately bringing 
viral replication under control, and reducing viral loads to a steady viral set point 
(Koup, Safrit et al. 1994; Moore, Cao et al. 1994). At the same time, humoral 
immune responses are elicited, and the presence of binding antibodies can be 
detected (seroconversion). Binding antibodies do not control viral replication.  
Control of viral replication by anti HIV-1 CD8+ cytotoxic T-lymphocytes allows for 
the partial recovery of CD4+ T cells (Figure 1.8), and the infected individual enters 
the chronic or asymptomatic phase of infection. This phase of HIV-1 infection can 
last from years to decades, during which time the infected individual remains 
clinically asymptomatic. During this time, the infected individual can mount 
vigorous cellular and humoral (including neutralizing antibody) immune responses 
against HIV-1. Eventually, viral loads escalate again and CD4+ T-cell counts 
decline to the extent where they can no longer support the immune system 
(Mellors, Munoz et al. 1997). This results in severe immune suppression, allowing 
for opportunistic infections to occur such as tuberculosis or Kaposi’s Sarcoma, 
culminating in the progression to AIDS (Pantaleo, Graziosi et al. 1993) (Figure 
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1.8). An AIDS diagnosis is made when the HIV-1 infected individual has a CD4 T-
cell count less than 200 cells/µl. Death usually occurs within 2 years of AIDS in the 
absence of antiretroviral therapy and the chance of death tends to increase with 
decreasing CD4 T-cell counts (WHO 2006). The introduction of highly active 
antiretroviral therapy (HAART) has substantially reduced the mortality and 
morbidity among HIV-1 infected individuals (Porter, Babiker et al. 2003).  
 
AIDS patients are placed on HAART, and with successful therapy viral loads can 
decrease to levels below detection (<50 RNA copies/ml) within 12 weeks 
(Markowitz, Saag et al. 1995). Unfortunately, the emergence of drug resistance in 
patients on HAART is inevitable. Patients placed on a first line treatment regimen 
usually have to adjust their treatment combinations to a new regimen once HIV-1 
drug resistant variants emerge (Little, Daar et al. 1999).       
 
The rate at which HIV-1 infected individuals progress to AIDS is variable and can 
be categorised into rapid progression, intermediate progression and slow 
progression (Buchbinder, Katz et al. 1994; Cao, Qin et al. 1995; Pantaleo and 
Fauci 1996). Ten to fifteen percent of HIV-1 infected individuals are rapid 
progressors, characterised by rapid CD4+ T-cell decline and hence progress to 
AIDS from as little as 6 months to a few years after initial infection (Anzala, 
Nagelkerke et al. 1995). The majority of infected individuals are intermediate 
progressors, characterised by disease progression to AIDS approximately 10 
years after initial infection. Only about 5% of infected individuals are characterized 
as long term non-progressors (LTNP) (Cao, Qin et al. 1995), elite controllers 
(Rosenberg, Billingsley et al. 1997) or slow progressors. Long term non 
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progressors are a group of individuals who maintain normal CD4 counts and 
remain asymptomatic for more than 7 years (Hogervorst, Jurriaans et al. 1995).  
Slow progressors are a subgroup of LTNP’s and are immunologically and clinically 
comparable to LTNP for about 4 years before showing a decline in CD4 cell 
counts and eventually clinical symptoms of AIDS within about 7 years (Hogervorst, 
Jurriaans et al. 1995). Elite controllers are another subgroup of LTNP’s and are 
characterized by their ability to maintain low viral loads (<50 RNA copies/ml) in the 
absence of antiretroviral therapy (Rosenberg, Billingsley et al. 1997). These 
groups of rare individuals, and are important to study further since they may 
harbour useful information about unexplored mechanisms of HIV-1 control.    
 
 
 
Figure 1.8: Graphical representation of HIV-1 disease progression. The dashed 
line with squares represents CD4 T-lymphocyte count (cells/mm3). The solid line 
with circles represents culturable plasma viremia and the dashed line with 
triangles represent viral load measured in viral RNA copies per ml. Figure copied 
from (Pantaleo, Graziosi et al. 1993).  
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1.4. Antibody responses to HIV-1  
 
Throughout HIV-1 infection an abundance of antibodies are elicited. These include 
binding antibodies, neutralizing antibodies and antibodies that work together with 
innate immune cells to kill off virus infected cells. The latter process is referred to 
as antibody dependent cell-mediated cytotoxicity (ADCC) and antibody dependent 
cell-mediated viral inhibition (ADCVI) (Sarmay, Lund et al. 1992). The majority of 
antibodies elicited early during HIV-1 infection are known as binding antibodies but 
are ineffective at preventing infection. By contrast, neutralizing antibodies aim to 
prevent viral entry and subsequent infection by binding to exposed regions on the 
Env, however once HIV-1 has entered into its target cells there is little or no role 
for these antibodies.  
 
1.4.1. ADCC and ADCVI  
 
ADCC antibodies bind to viral epitopes exposed on the surface of HIV-1 infected 
cells. The biological activity of ADCC antibodies is mediated through the FC region 
of the antibody (Sarmay, Lund et al. 1992). FC receptors are expressed on natural 
killer cells, monocytes, macrophages, dendritic cells and neutrophils (Sarmay, 
Lund et al. 1992). ADCC occurs by a 3-way interaction between an infected target 
cell which displays antigens on its surface, ADCC antibodies and an effector cell 
expressing the FC receptor. These interactions ultimately result in the killing of the 
infected target cell (Baum, Cassutt et al. 1996). ADCVI also involves the 
interaction between a target cell, ADCVI antibody and an effector cell. However, 
rather than causing cell death, ADCVI antibodies aim to reduce the viral output 
from infected target cells. It has been confirmed that HIV-specific ADCC and 
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ADCVI antibodies are present in most HIV-1 infected individuals during early 
infection (Ljunggren, Bottiger et al. 1987), however with disease progression, 
natural killer cells lose their function and are unable to mediate ADCC activity 
(Baum, Cassutt et al. 1996). ADCC antibodies differ from neutralizing antibodies; 
ADCC antibodies target infected cells and result in cell killing whereas neutralizing 
antibodies target cell free virus and results in viral inhibition.   
 
1.4.2. Binding antibodies 
 
Binding antibodies are characterized by their inability to prevent viral infection and 
are produced at high levels throughout the lifetime of an infected individual. These 
antibodies recognize highly immunogenic and variable regions of the HIV-1 virion. 
Even though they do not prevent viral entry, binding antibodies are useful as a 
diagnostic indication of whether the virus is present or not. For example, the 
detection of anti-p24 (core) antibodies by enzyme-linked immunosorbant assay 
(ELISA) is used as a diagnostic test to detect seroconversion in the acute phase of 
infection (Daar, Little et al. 2001).  
 
 1.4.3. Neutralizing antibodies 
 
1.4.3.1. Autologous neutralizing antibodies 
 
Most HIV-1 infected individuals produce antibodies capable of inhibiting their own 
virus (autologous virus) but incapable of neutralizing heterologous viruses and are 
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known as autologous neutralizing antibodies (Arendrup, Nielsen et al. 1992). 
These antibodies target immunogenic, exposed regions of the HIV-1 virion, 
however their neutralization capacity is transient due to viral mechanisms to 
escape antibody recognition (Arendrup, Nielsen et al. 1992). Once the humoral 
immune system recognizes a particular viral variant and generates an appropriate 
antibody response, a new escape variant will subsequently emerge (Arendrup, 
Nielsen et al. 1992), possibly due to a combination of the immune pressure and 
the error prone reverse transcriptase. Therefore autologous neutralizing antibody 
responses tend to lag behind viral escape variants. 
 
A study reported on the detection of autologous Nab as early as 52 days after 
detection of HIV-specific antibodies in acutely infected patients (Wei, Decker et al. 
2003). Another study by evaluated autologous and heterologous neutralizing 
antibody responses in 14 HIV-1 subtype C acutely infected individuals (Gray, 
Moore et al. 2007). Env-clones were used which were obtained within the first 2 
months of infection. Their results revealed that potent autologous neutralizing 
antibodies are produced within 3 to 12 months post-infection with an increase in 
autologous antibody production observed within the first 6 months (Gray, Moore et 
al. 2007). Interestingly, it was noted that potent autologous neutralization 
correlated with shorter Env variable region lengths as well as the presence of 
fewer glycoslation sites in the V1 to V2 region of Env (Gray, Moore et al. 2007). 
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1.4.3.2. Broadly neutralizing antibodies 
 
Neutralizing antibodies with cross reactivity have been identified in a minority of 
HIV-1 infected individuals, and have the unique ability to effectively neutralize 
multiple viral isolates across diverse strains and subtypes. Target epitopes of 
neutralizing antibodies include the Env glycoprotein subunits, gp120 and gp41. 
 
Numerous studies have evaluated and characterized the neutralizing antibody 
responses elicited during natural infection among serum from HIV-1 infected 
individuals worldwide. For example, a study by van Gils et al. (2009) evaluated 
neutralizing antibody responses in 35 participants with rapid or slow HIV-1 
infection. The findings from this study suggest that neutralizing antibody titers 
increase with time during infection. A study by Binley et al. (2008) characterized 
the epitope specificities recognized by 24 subtype B and C infected participants 
with broadly neutralizing serum. They found that the majority of neutralizing 
antibodies present in these individuals recognized unidentified epitopes in addition 
to the more conserved CD4 and co-receptor binding sites.  
 
Broadly neutralizing antibodies are rarely elicited during natural infection. However 
a few broadly neutralizing antibodies have been characterized and isolated from 
HIV-1 positive individuals. These include IgG1b12 (Roben, Moore et al. 1994), 
2G12 (Trkola, Purtscher et al. 1996), PG9, PG16 (Walker, Phogat et al. 2009), 
VRC01 and VRC02 (Zhou, Georgiev et al. 2010) that target the gp120, as well as 
2F5 (Muster, Steindl et al. 1993), 4E10 (Buchacher, Predl et al. 1994) and Z13 
(Zwick, Labrijn et al. 2001) which target the gp41. 
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The broadly neutralizing monoclonal antibody IgG1b12 recognizes the highly 
conserved CD4 binding site on gp120 and acts as a competitive inhibitor of CD4 
(Roben, Moore et al. 1994). IgG1b12 interacts with its epitope via its unique 
extended long complementarity-determining region, CDR3 loop from the variable 
domain of its heavy chain. (Roben, Moore et al. 1994) (Figure 1.9). The CD4 
binding site on gp120 is a recessed pocket which forms a contact site for a Phe-43 
amino acid residue that protrudes from the loop on the CD4 molecule (Wyatt and 
Sodroski 1998). Without this interaction gp120 binds too quickly to CD4 and will 
not allow the fusion process to occur (Wyatt and Sodroski 1998). Upon binding to 
its epitope, IgG1b12 induces little entropic and conformational changes suggesting 
a favourable fit into the CD4 binding site of gp120 (Kwong, Doyle et al. 2002). In a 
study by Binley et al. (2004), IgG1b12 was evaluated for its cross reactivity against 
a diverse panel of primary and pseudoviruses representing all major subtypes (A, 
B, C, D, F, and AC and AE recombinants) as well as 25 primary isolates. IgG1b12 
was able to neutralize 50% of all tested viruses including viruses from all subtypes, 
confirming that IgG1b12 is a potent broadly neutralizing antibody (Binley, Wrin et 
al. 2004). 
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Figure 1.9: X-ray crystallography capturing IgG1b12 bound to the CD4 binding 
site on gp120. Figure adapted from (Chen, Kwon et al. 2009).  
 
Two recently identified somatically related monoclonal antibodies, PG9 and PG16 
(Figure 1.10) were isolated from cloned B cells of a subtype A infected patient 
(Walker, Phogat et al. 2009). These 2 antibodies have the ability to neutralize 70 – 
80% of circulating HIV-1 strains/subtypes by recognizing conserved epitopes in 
the V2 and V3 loops of trimeric gp120 (Walker, Phogat et al. 2009). Structural 
analysis of PG9/PG16 has revealed 3 distinct features; N-linked glycosylation, 
affinity maturation and the longest observed CDR H3 region in human antibodies 
(Pancera, McLellan et al. 2010). The extensive glycosylation was found not to be 
required for neutralization. The long CDR H3 region forms an axe-shaped 
 gp120 
 CD4 binding 
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subdomain (Figure 1.10) which comprises about 42% of the CDR surface. Affinity 
maturation was shown to play a major role in the neutralization breadth of these 2 
antibodies (Pancera, McLellan et al. 2010).   
 
Wu et al. (2010) have recently developed antigen resurfaced glycoproteins that 
are specific for the CD4 binding site of gp120. These were used as probes to 
identify sera with neutralizing antibodies to the CD4 binding site and subsequently 
isolate B cells from identified individuals to produce monoclonal antibodies. As a 
result, three potent neutralizing antibodies were identified, two somatic variants 
VRC01 (Figure 1.11) and VRC02 as well as VRC03. VRC01 and VRC02 showed 
a striking neutralization breadth of 91% against viral isolates across diverse 
subtypes (A, B, C, D, G) as well as circulating recombinant forms (CRF01_AE and 
CRF07_BC) (Wu, Yang et al. 2010; Zhou, Georgiev et al. 2010). VRC03 showed 
less neutralization potency than VRC01 and VRC02, with the ability to neutralize 
57% of HIV-1 diverse primary isolates, including subtypes A, B, C, D, G and 
CRF01_AE and CRF07_BC (Wu, Yang et al. 2010). VRC01 binds to a highly 
conserved portion of the CD4 binding site. Interestingly there is a significant 
correlation to the residues on gp120 involved in CD4 binding as well as VRC01 
binding (Zhou, Georgiev et al. 2010). This unique antibody partially mimics the 
CD4 molecule with 73% homology with the CD4 N-terminal domain (Zhou, 
Georgiev et al. 2010). An interesting feature of the VRC01 antibody is that it 
targets the outer domain of the CD4 binding site which is occluded by glycan 
shields (Zhou, Georgiev et al. 2010). The VRC01 light chain makes contact with 
the N-linked glycan at residue 276 on gp120; therefore VRC01 uses the glycan for 
binding rather than being occluded by it (Zhou, Georgiev et al. 2010). Only 13% of 
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contact is made with the bridging sheet of gp120 and is found not to be essential 
for binding. By contrast, the CD4 molecule makes 33% of its contact with the 
gp120 bridging sheet and is essential for binding (Kwong, Wyatt et al. 1998). The 
Phe43CD4 interaction with gp120 is not observed in VRC01-gp120 binding however 
the Arg59CD4 interaction with gp120 is mimicked by VRC01 (Zhou, Georgiev et al. 
2010).  
 
 
 
Figure 1.10: Crystal structure of the antigen binding fragment (Fab) of neutralizing 
antibody PG16. Heavy and light chains are represented in tan and blue 
respectively and the CDR H3 region is shown in red. The variable regions 
comprise the top half of the image and the constant regions comprise the bottom. 
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A single N-linked glycan is shown by the green stick representation.  Figure copied 
from (Pancera, McLellan et al. 2010). 
 
 
 
Figure 1.11: Crystal structure of gp120 complexed with the neutralizing antibody, 
VRC01. Figure adapted from (Zhou, Georgiev et al. 2010).  
 
The monoclonal antibody 2G12 has a unique structure in which the arms of the 
variable heavy chain domains are swapped (Figure 1.12), and is unique in its 
ability to target gp120’s non immunogenic glycan shield (Trkola, Purtscher et al. 
1996) (Figure 1.12). 2G12 recognizes glycans at residues 332 and 392 and is 
dependant on glycans at positions 295, 339 and 386 (Scanlan, Pantophlet et al. 
2002). 2G12 has been shown to bind to Manα1-2Man at the D1 and D3 terminals 
of an oligomannose sugar on the gp120 silent face (Calarese, Lee et al. 2005). 
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Similar to IgG1b12, 2G12 induces little conformational changes when bound to its 
epitope (Kwong, Doyle et al. 2002).   
2G12 was tested in a neutralization assay against pseudoviruses representing 
subtypes A, B, C, D, F, AC and AE as well as 25 primary viral isolates in order to 
determine the neutralization breadth of the antibody (Binley, Wrin et al. 2004). 
Results revealed that 2G12 could effectively neutralize 41% of the tested viruses 
none of which were from subtype C or E (Binley, Wrin et al. 2004). The fact that 
2G12 does not exhibit cross neutralization against subtype C isolates may be due 
to the lack of a glycan at position 295 at the N-terminal base of the V3 loop in 
subtype C viruses (Binley, Wrin et al. 2004). 
 
 
 
Figure 1.12: Schematic diagram of 2G12 bound to the Env spike. The heavy 
chains of 2G12 heavy chains are shown in dark blue and light red and the light 
chains are shown in light blue. Sugar moieties are indicated in dark red. The 
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gp120 trimer is shown in dark grey, light grey and green with potential N-linked 
glycosylation sites depicted in yellow. The gp41 is shown in purple with the viral 
membrane depicted in blue. Figure adapted from (Burton, Stanfield et al. 2005). 
 
2F5, 4E10 and Z13 are potent cross reactive neutralizing antibodies which 
recognize overlapping epitopes in the conserved membrane proximal external 
region (MPER) at the base of gp41 (Muster, Steindl et al. 1993; Buchacher, Predl 
et al. 1994; Zwick, Labrijn et al. 2001) (Figure 1.13). 2F5 recognizes the epitope 
ELDKWA and the DKW motif is the minimum core requirement for 2F5 
neutralization (positions 664-666 on gp41) (Stiegler, Kunert et al. 2001). 2F5 
effectively neutralizes isolates from subtypes A, B, D and E however shows poor 
neutralization capacity against subtype C isolates, possibly due to the fact that 
most subtype C viruses have a DSW motif in place of DKW (Purtscher, Trkola et 
al. 1996; Stiegler, Kunert et al. 2001). 4E10 was previously described to recognize 
the NWFDIT epitope; however Binley et al. (2004) showed that the minimum 
requirement for 4E10 neutralization is the WFXI motif. The authors also confirmed 
that 4E10 has potent cross-reactive neutralization activity against 90 viruses from 
subtypes A, B, C, D, F, G, J and AC, AE, AG, BF and BG recombinants. The 
extensive cross reactive neutralization capacity of 2F5 was confirmed by its ability 
to recognize and bind to 31 variations of the MPER (Bryson, Julien et al. 2009). 
2F5 also exhibits faster binding to the MPER and is more thermodynamically 
favourable compared to 4E10 binding (Dennison, Stewart et al. 2009); the slow 
binding of 4E10 could be attributed to the membrane immersion depth of its 
epitope compared to the 2F5 epitope (Dennison, Stewart et al. 2009). Dennison et 
al. (2009) showed that the neutralization breadth of antibodies targeting the MPER 
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is dependant of the membrane immersion depth of their epitopes.  Z13 was 
isolated in 2001 from an antibody phage display library and was shown to 
recognize an epitope similar to that of 4E10 but with the ability to neutralize a 
limited set of primary viruses (Zwick, Labrijn et al. 2001). Recently, a high affinity 
variant of Z13 designated Z13e1 was isolated recognising an epitope overlapping 
that of 2F5 and 4E10 (WASLWNWFDITN) and exhibited about 100-fold better 
affinity for the MPER as well as enhanced neutralization capacity against sensitive 
strains of HIV-1 (Nelson, Brunel et al. 2007).   
 
 
 
 
Figure 1.13: Animated model of the HIV-1 trimeric envelope spike. The HIV-1  
gp120 is illustrated in blue and the membrane proximal external region (MPER) of 
gp41 is depicted in green. The 2F5, 4E10 and Z13 recognition sites are also 
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indicated. An IgG molecule, represented in orange is shown to scale in proximity 
to the indicated antibody binding regions. Figure copied from (Zwick, M.B et al. 
2001). 
 
There are several antibodies that have been well described that exhibit some 
degree of neutralization against HIV-1. Previously, the V3 loop of gp120 was 
referred to as the principle neutralizing domain/epitope (Hwang, Boyle et al. 1991). 
However this was only true for laboratory adapted viruses (Hwang, Boyle et al. 
1991). Primary virus isolates have been shown to sequester the V3 region making 
it inaccessible to neutralizing antibodies, therefore antibodies directed against the 
V3 loop are generally type specific with limited neutralization capacity (Bou-Habib, 
Roderiquez et al. 1994).   
 
The anti-V3 neutralizing antibody 447-52D shows moderate neutralization breadth 
by interacting with a conserved GPGR motif in subtype B isolates via its long CDR 
H3 loop in a sequence independent manner (Conley, Gorny et al. 1994). However, 
for CCR5-utilizing viruses, the V3 loop is poorly immunogenic before CD4 binding 
therefore 447-52D has limited neutralization breadth against these isolates (Lusso, 
Earl et al. 2005). Interestingly, 447-52D has been shown to neutralize 45% of 
subtype B viruses but only 7% of other subtypes (A, B, C, D, F, AC and AE as well 
as 25 primary viral isolates) (Binley, Wrin et al. 2004). Neutralization of non-B 
subtypes largely depends on the presence of the GPGR motif (Binley, Wrin et al. 
2004).   
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Another monoclonal antibody 2219 (Gorny, Williams et al. 2002) recognizes the 
V3 loop but with less efficiency than 447-52D. Unfortunately, HIV-1 is capable of 
escaping recognition by both these antibodies by reducing its accessibility to the 
extent where 447-52D and 2219 cannot recognise their epitopes anymore (Gorny, 
Williams et al. 2002). The monoclonal antibody, 17b recognizes CD4 induced 
(CD4i) epitopes, in particular the gp120 bridging sheet essential for gp120-co-
receptor binding (Zhang, Godillot et al. 2001) (Figure 1.14). Unfortunately 17b is 
not able to effectively neutralize a diverse range of isolates. This could be due to 
the fact that the co-receptor binding site is only transiently exposed on gp120 
during viral fusion and therefore access to the 17b epitope is limited (Labrijn, 
Poignard et al. 2003). Although CD4i antibodies are elicited in most HIV-1 infected 
individuals, they are unable to access their epitopes before CD4 binding and are 
therefore poorly neutralizing (Labrijn, Poignard et al. 2003; Decker, Bibollet-Ruche 
et al. 2005).     
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Figure 1.14: Ribbon diagram of gp120 complexed with neutralizing antibody 17b. 
Figure adapted from (Kwong, Wyatt et al. 1998). 
 
1.4.4 Antibodies as therapeutics 
 
Neutralizing antibodies are highly effective in controlling HIV-1 replication in vitro. 
To have a better understanding of the role of neutralizing antibodies in controlling 
HIV-1 infection in vivo, passive immunization studies have been conducted using 
animal models and more recently in human clinical trials. Conley et al. (1996) 
demonstrated the ability of the monoclonal antibody 2F5 to partially protect 
chimpanzees against intravenous challenge with a primary virus. In this study, 2 
chimpanzees were intravenously infused with the 2F5 monoclonal antibody and 
subsequently challenged with a primary HIV-1 isolate. Among the control 
gp120 
2d CD4 
17b heavy 
chain 
17b light 
chain 
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chimpanzees which received no antibody, infection was established immediately 
and seroconversion occurred within 4 weeks. By contrast, seroconversion 
occurred by week 14 in the 2F5 infused chimpanzees (Conley, Kessler et al. 
1996). Using non human primate models to study the role of neutralizing 
antibodies in HIV-1 infection is difficult because most HIV-1 primary isolates do not 
infect non human primates. Mascola et al. (1999) demonstrated the use of a 
simian/human immunodeficiency virus (SHIV) using the Env of a primary isolate 
(HIV-89.6). HIV-1 immune globulin (HIVIG) as well as 2 monoclonal antibodies 
2F5 and 2G12 were passively infused into rhesus macaques in a double dose 
(2F5,2G12) or triple dose (HIVIG, 2F5, 2G12) 24 hours before viral challenge 
(Mascola, Lewis et al. 1999). Out of 6 macaques that received the triple dose, 3 
were completely protected from viral challenge and 2 out 3 macaques that 
received the double dose showed reduced viral loads (Mascola, Lewis et al. 1999). 
 
The passive immunization of monoclonal antibodies in animals has provided 
useful information of the control of these antibodies in vivo. However human 
studies are still needed to evaluate the safety and tolerability of these antibodies in 
humans. The broadly neutralizing monoclonal antibodies, 2F5, 2G12 and 4E10 
were evaluated for safety and tolerability in humans during a phase I clinical trial 
(Armbruster, Stiegler et al. 2002). These 3 monoclonal antibodies were 
subsequently used in a proof-of-concept study using human subjects (Trkola, 
Kuster et al. 2005). This study demonstrated that high doses of a cocktail of 3 
monoclonal antibodies (2F5, 2G12 and 4E10) resulted in delayed viral rebound in 
patients who already had suppressed viral loads by ART before the passive 
administration of the antibodies (Trkola, Kuster et al. 2005). Eight chronically 
37 
 
infected and 6 acutely infected patients were included. Interestingly, most of the 
inhibitory effects of the cocktail could be attributed to 2G12. 2G12 was found to 
have a significantly slower systemic clearance than 4E10 or 2F5 (Trkola, Kuster et 
al. 2005). The plasma samples from this study were later assessed to determine 
estimates for effective neutralization titers (Trkola, Kuster et al. 2008). The 
contribution of each monoclonal antibody to the total neutralization activity in 
patients was assessed. Their findings suggested that the stage of HIV-1 infection 
influenced the quantities of neutralizing antibody needed. For example, lower 
neutralizing antibody levels showed an effect in acute infection compared to 
chronic infection (Trkola, Kuster et al. 2008). These findings suggest that a 
therapeutic antibody-based vaccine may be more efficient if administered early in 
HIV-1 infection.  
 
In another proof-of-concept study 3 monoclonal antibodies (2G12, 2F5 and 4E10) 
were passive administered to 10 HIV-1 infected individuals who received ART 
during acute or chronic infection (Mehandru, Vcelar et al. 2007). 2G12, 2F5 and 
4E10 were intravenously administered at equal concentrations. Results showed 
that 8 out of 10 patients experienced viral rebound and 2 patients remained 
aviremic throughout the study. Seven out of 8 patients with viral rebound showed 
resistance to 2G12 and the depletion of CD4 T-cells (Mehandru, Vcelar et al. 
2007).   
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1.4.5 Autoreactivity of broadly Neutralizing antibodies and other anti-HIV-1 
antibodies  
 
The fact that antibodies to the MPER can be elicited in some individuals is 
noteworthy, since the 2F5 and 4E10 epitopes are in close proximity to the host 
plasma membrane. Therefore, such antibodies could show auto reactivity and 
should be negatively selected for during B-cell differentiation (Haynes, Fleming et 
al. 2005). 2F5, 4E10 and Z13 do show some degree of auto reactivity to a host 
phospholipid, cardiolipin (Golding, Robey et al. 1988; Haynes, Fleming et al. 
2005). Anti-cardiolipin (aCL) antibodies are observed in patients with the auto 
immune disorder antiphospholipid syndrome (APS) (Mackworth-Young, Loizou et 
al. 1989). They are also found in HIV-1 infected patients with systemic lupus 
erythematosus (SLE) (Petrovas, Vlachoyiannopoulos et al. 1999). 4E10 has also 
been shown to react with SLE auto antigen SS-A/Ro.B12 as well as double-
stranded DNA (dsDNA), centromere B, and histones (Haynes, Fleming et al. 2005; 
Haynes, Moody et al. 2005). This has been hypothesized to be a result of the 
cross reactivity between self and non-self antigens (Haynes, Fleming et al. 2005), 
or molecular mimicry (Deas, Liu et al. 1998).  
 
B-cell tolerance is controlled in CD4+ T-lymphocytes. T-dependent antigens 
require the recognition of both T- and B-cells in order for an effective humoral 
immune response to occur and the appropriate antibody to be released. During the 
maturation process of T-cells in the thymus and B-cells in the bone marrow, they 
are exposed to host antigens for positive and negative selection. Immune cells that 
are able to recognize host antigens can induce tolerance (Starr, Jameson et al. 
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2003) however during HIV-1 infection, thymic function is severely impaired 
(Douek, McFarland et al. 1998). This may provide a possible explanation for the 
production of anti-self antibodies. 
 
A study by Bermas et al. (1994) showed that sera from HIV uninfected individuals 
with SLE had antibodies directed against conserved regions of gp120. In addition, 
another study showed that a single chain antibody fragment isolated from a lupus 
antibody phage library had the ability to bind to the conserved CD4 binding site on 
gp120. The antibody fragment also showed good neutralizing activity against X4 
and R5 HIV-1 strains from subtypes B, C and D (Karle, Planque et al. 2004). 
Interestingly, It has also been documented that the light chain portion of antibodies 
isolated from lupus patients can neutralize gp120 (Nishiyama, Karle et al. 2007).   
 
Detection of 2G12-like antibodies was not associated with any auto antibodies 
however detection of the broadly neutralizing antibody IgG1b12 was associated 
with the presence of aCL and anti cytoplasmic antibodies (Martinez, Diemert et al. 
2009). During the budding process by which HIV-1 exits the cell, HIV-1 takes 
certain host proteins with it from the lipid membrane, therefore antibodies against 
self antigens found in patients with autoimmune diseases may cross react with 
HIV-1 Env proteins found close to the host derived viral membrane such as the 
2F5, 4E10 and Z13 epitopes (Scherl, Posch et al. 2006). 
 
The auto reactivity of the above-mentioned broadly neutralizing antibodies raises 
concern regarding the elicitation of such antibodies through a vaccine 
incorporating the Env glycoprotein and provides a possible explanation for the rare 
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occurrence of these antibodies during natural infection (Gray, Taylor et al. 2009; 
Martinez, Diemert et al. 2009). One broadly neutralizing antibody in particular, m44 
targets an epitope within the gp41 region and is of special interest because it can 
neutralize diverse strains of HIV-1 isolates without any reactivity to self antigens 
such as cardiolipin (Zhang, Vu et al. 2008). From these findings, it is evident that 
patients with autoimmune diseases are worthwhile investigating further for the 
presence of broadly neutralizing antibodies against HIV-1. 
 
1.4.6 Features of Env that make it difficult to elicit broadly neutralizing 
antibodies 
 
HIV-1 employs various different escape mechanisms which allow the virus to avoid 
and escape antibody recognition. Firstly, the conformational flexibility of the gp120 
creates thermodynamic and kinetic barriers to neutralization and complex tertiary 
and quaternary structures renders a large portion of the functional Env trimer 
inaccessible to these antibodies (Wyatt and Sodroski 1998).  
 
The extensive glycosylation of gp120 which masks conserved epitopes renders a 
large portion of the protein poorly immunogenic, and the re-arrangement of the 
glycan shield without altering the functionality of Env, allows for antibody escape 
(Wei, Decker et al. 2003). The CD4 binding site and co-receptor binding sites are 
shielded by variable regions of the Env. While these immunogenic regions are 
targeted by neutralizing antibodies during the course of infection the virus is 
however able to continuously escape antibody responses by sequence diversity 
(Burton, Stanfield et al. 2005). In addition, there is extensive sequence diversity as 
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a result of the error prone reverse transcriptase enzyme. This results in non 
synonymous changes in important epitopes leading to amino acid substitutions, 
insertions and/or deletions to avoid antibody recognition. In addition there is 
sequence diversity among different subtypes of HIV-1, with up to 35% of Env 
sequence diversity between the different HIV-1 subtypes (Gaschen, Taylor et al. 
2002).   
 
Furthermore, due to the labile gp120-gp41 interaction, monomeric gp120 is shed 
from the virion and acts as a major immunogen in vivo, eliciting high titers of non-
neutralizing or binding antibodies by exposing epitopes that are buried or not 
formed on the functional trimeric Env spike (Rong, Li et al. 2009). In addition, 
functional epitopes that could inhibit gp120-CD4 interactions or gp120-co-receptor 
interactions and epitopes exposed during viral fusion are only transiently exposed, 
thus not allowing sufficient time for the production of the appropriate antibody.  
1.5. Vaccine development  
 
Numerous attempts have been made in the development of an HIV-1 vaccine but 
have been met with little success. Previous traditional vaccine strategies have 
focused on live attenuated viruses, whole killed viruses and protein subunits 
(Baba, Liska et al. 1999; Learmont, Geczy et al. 1999). These approaches have 
proven successful against other viruses such as the influenza virus but raise great 
safety concerns with regard to HIV-1. More recent vaccine strategies have made 
use of gene delivery technologies such as plasmid DNA vaccines or recombinant 
viral vectors expressing HIV-1 antigens (Casimiro, Chen et al. 2003). 
Unfortunately, plasmid DNA vaccines require high doses in humans in order to 
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elicit effective immune responses (Graham, Koup et al. 2006). Therefore recent 
HIV-1 vaccine candidates comprise recombinant viral vectors (attenuated or 
replication-incompetent viruses) such as adenoviruses (Priddy, Brown et al. 2008) 
or poxviruses (Harari, Bart et al. 2008).   
 
The international AIDS vaccine initiative (IAVI) is an organization that aims to 
develop an effective HIV-1 vaccine and ensure its delivery to countries where it is 
most needed such as Sub Saharan Africa and Asia (Chataway and Smith 2006). 
IAVI funds potential vaccine candidates at the developmental stage as well as 
clinical trials. Currently, IAVI operates in 22 countries and works closely with it’s 
scientific partners who perform research on the development of an HIV-1 vaccine 
(Chataway and Smith 2006). Recently, in October 2010 IAVI announced the start 
of a phase I prime/boost clinical trial known as B003/IPCAVD-004 (IAVI 2010). 
This trial aims to evaluate the safety and immunogenicity of the 2 vaccine 
candidates (B003) and (IPCAVD-004) in a regimen where vaccines will be given 
sequentially in an attempt to boost immune responses to HIV-1. The vaccine 
candidates comprise adenoviral vectors (serotype 26 and 35) containing the Env 
gene. The study aims to include 212 healthy participants between the ages of 18 
and 50 (IAVI 2010). An overview and update of all HIV-1 vaccine human clinical 
trials to date can be found on http://www.iavi.org. 
        
A vaccine trial by Merck made use of a candidate which comprised a recombinant 
adenovirus vector that expressed HIV-1 subtype B gag, pol and nef genes (Priddy, 
Brown et al. 2008). However participants with pre-existing antibodies against the 
adenovirus vector showed suppressed immune responses to the vaccine 
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(Kostense, Koudstaal et al. 2004). Phase 2b proof of concept studies were 
subsequently initiated to evaluate 3000 subjects for HIV-1 specific cellular immune 
responses elicited by this vaccine regimen. This was known as the STEP study 
and was conducted in America, Caribbean and Australia (McElrath, De Rosa et al. 
2008). Unexpectedly, this study was brought to an early halt due to safety 
concerns. It was hypothesized that the recombinant adenovirus vector may have 
increased the acquisition of HIV-1 infection in some individuals (Sekaly 2008; 
Watkins, Burton et al. 2008).     
 
The first efficacy trial (Vax004) began in 1998. The Vax004 trial was aimed at 
determining the efficacy of a recombinant bivalent subtype B gp120 vaccine 
(AIDSVAX) in preventing sexual transmission of HIV-1 in North America and the 
Netherlands, where subtype B infections are prevalent (Berman 1998). The trial 
included 5108 men who have sex with men (MSM) and 309 high risk women. 
Although the AIDSVAX vaccine elicited strong antibody responses, it failed to 
protect against HIV-1 infection and had no effect on the viral loads of participants 
who acquired HIV-1 infection after vaccination (Gilbert, Ackers et al. 2005). 
Interestingly, a renewed interest in the Vax004 trial began last year (Gilbert, Wang 
et al. 2010). Gilbert et al (2010) analysed the neutralizing antibody responses in 
the participants of the Vax004 trial against a panel of very sensitive (tier 1) and 
moderately sensitive (tier 2) HIV-1 strains. Results revealed that the participants 
produced high titers of neutralizing antibodies against the tier 1 viruses but little or 
weak antibody responses against the panel of tier 2 viruses. The authors reported 
that the overall lack of tier 2 virus neutralization was consistent with the lack of 
antibody protection in the Vax004 trial.       
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The latest results from the RV144 trial (using a canary pox viral vector expressing 
gp120, gag and pol to prime immune responses followed by the AIDSVAXgp120 
vaccine to boost the immune response) showed, for the first time, a statistically 
significant 30% protective efficacy (RerksNgarm, et al., 2009). This suggests that 
an effective HIV-1 vaccine should include components that elicit responses in both 
arms of the immune system. 
 
Although it has been a great challenge to elicit effective broadly neutralizing 
antibody responses in humans through vaccination, progress has been made in 
understanding the Env structure, viral escape mechanisms and the mechanisms 
by which identified rare neutralizing antibodies exhibit cross reactivity (Hoxie 
2010). The RV144 Thai trial provided scientists with some hope that a preventative 
HIV-1 vaccine is possible (Rerks-Ngarm, Pitisuttithum et al. 2009). The exact 
mechanism of protection in this trial is not clearly defined however it is believed by 
some that the low level of protection may be a result of a combination of 
antibodies including neutralizing antibodies, antibodies that mediate ADCC, 
antibodies that mediate the induction of β chemokines or binding antibodies and 
CD4i antibodies (Rerks-Ngarm, Pitisuttithum et al. 2009). The results from 
previous vaccine studies highlights the urgent need to better understand the 
humoral immune response towards HIV-1 for more effective vaccine design in the 
future. While broadly neutralizing antibodies are infrequently elicited among 
infected individuals for reasons not clearly defined, B-cell tolerance mechanisms 
and viral escape mechanisms are however believed to play a major role. A better 
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understanding of why this occurs would assist in eliciting such responses through 
vaccination (Srivastava, Ulmer et al. 2005).  
 
Another promising approach for identifying a vaccine candidate is to dissect the 
natural immune response in individuals who are able to control HIV-1 infection 
such as slow progressors. Although the mechanism of control among slow 
progressors remains elusive, several studies provide possible explanations. A 
study showed that slow progressors have decreased Env function resulting in 
reduced replication capacity, possibly contributing to viral suppression (Lassen, 
Lobritz et al. 2009). Another study (Chien, Chen et al. 2004) demonstrated that 
antibodies directed against the CD4 binding site on gp120 interferes with the 
presentation of gp120 to T-helper cells and hence further weakens the immune 
system of HIV-1 infected individuals. Interestingly they showed that slow 
progressors have very little or no anti-CD4 antibodies compared to rapid 
progressors who have higher anti-CD4 antibody responses (Chien, Chen et al. 
2004). Host genetic factors may also contribute to delayed disease progression 
such as HLA polymorphisms or co-receptor polymorphisms (Roger 1998).  
 
1.6. Relevance of this study 
 
The identification of few broadly neutralizing antibodies to date have provided 
valuable information of conserved epitopes as potential vaccine targets. However, 
HIV-1 specific broadly neutralizing antibody responses are rarely elicited during 
natural infection, illustrating the poor immunogenicity of their epitopes. Some 
individuals however, produce neutralizing antibodies capable of inhibiting diverse 
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viral isolates across different subtypes. A better understanding of these individuals 
may be useful in providing information for vaccine development aimed at eliciting 
similar immune responses (Binley 2009). The auto-reactivity of 2F5, 4E10 and 
IgGb12 may explain why these antibodies are rarely produced in HIV infected 
individuals with B-cell tolerance mechanisms preventing their production. If this is 
the case, then patients with auto immune diseases display some protection 
against HIV-1 (Haynes, Fleming et al. 2005).  
 
None of the above mentioned neutralizing antibodies were derived from HIV-1 
subtype C infected individuals and efforts to generate monoclonal antibodies from 
these individuals have lagged. Three identified broadly neutralizing antibodies 
show less potency against subtype C viral isolates. For example, IgG1b12 
effectively neutralizes 75% of subtype B isolates and less than 50% of non-
subtype B strains (Binley, Wrin et al. 2004), and 2G12 and 2F5 have limited 
neutralization capacity against subtypes A and C (Gray, Meyers et al. 2006; Blish, 
Nedellec et al. 2007).  It is therefore important to systematically screen for the 
presence of HIV-1 subtype C specific neutralizing antibody responses among 
infected patients, and to generate HIV-1 specific broadly neutralizing monoclonal 
antibodies.  
 
The overall objective of this study was to identify individuals with broad cross-
reactive neutralizing antibodies against HIV-1 subtype C from a range of four 
different cohorts. These included HIV-1 negative and positive patients with 
autoimmune diseases, antiretroviral (ARV) drug-naïve AIDS patients, HIV-1 
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positive patients failing first line therapy and HIV-1 positive patients classified as 
slow progressors.  
 
This was achieved by the following aims: 
 
1.6.1. To collect, isolate and store serum, plasma, peripheral blood 
mononuclear cells and matched bone marrow from participants with 
autoimmune disease (HIV-1 seronegative or seropositive).  
 
1.6.2. To collect plasma samples from HIV-1 infected slow progressors, ARV 
drug naïve patients and HIV-1 positive patients failing first line therapy. 
 
1.6.3. To establish a pseudovirion-based neutralizing antibody assay. 
 
1.6.4. To screen the serum and plasma samples from all four cohorts for the 
presence of greater than average breadth of antibody neutralization using the  
pseudovirion-based neutralizing antibody assay.  
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CHAPTER 2:  MATERIALS AND METHODS 
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2.1 Study population  
 
A total of 40 patient samples were collected or available for the purposes of this 
study. These included participants from a CT cohort (9), FV cohort (11), DR cohort 
(10) and JM cohort (10). The available demographic and clinical data of the 
participants is shown in Table 2.1. 
 
The CT cohort included plasma samples from nine HIV-1 seropositive slow 
progressor patients obtained from Professor Caroline Tiemessen (National 
Institute for Communicable Diseases). Eleven HIV-1 subtype C seropositive 
plasma samples from antiretroviral (ARV) drug naive patients comprised the FV 
cohort and were available for use in the laboratory (Connell, Michler et al. 2008). 
Ten plasma samples from HIV-1 subtype C seropositive ARV treatment 
experienced patients who were failing first line therapy were available for use in 
the laboratory and made up the DR cohort.   
 
The JM cohort consisted of peripheral blood with matching bone marrow samples 
obtained from patients referred to the Haematology Department at the Charlotte 
Maxeke Johannesburg Academic Hospital for bone marrow aspiration as part of 
their routine diagnostic workup. Ten participants were selected over a period of 12 
months (2009) according to the following inclusion criteria; Participants must have 
a clinical indication for performing a bone marrow aspirate procedure. Participants 
must have their HIV serostatus already established, Participants must have a 
result of autoimmune screen or have had clinical assessment of autoimmune 
disease status, and participants must be willing to sign an informed consent form.  
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Bone marrow aspirations were performed as per standard procedure by Professor 
Johnny Mahlangu and an additional 5 ml of bone marrow was collected into a 
PAXgene blood tube (Qiagen, Maryland, USA) or Ethylene Diamine Tetra acetic 
Acid (EDTA) blood tube for the study. Five millilitres of matching peripheral blood 
was collected into EDTA and serum separating tubes (SST). The blood and 
matching bone marrow samples were transported to the laboratory at room 
temperature. 
 
2.1.1 Ethics 
Informed Consent was obtained from each study participant prior to sample 
collection. Ethics clearance was obtained from the University of the Witwatersrand 
committee for research on human subjects (protocol number M090547, (Appendix 
A.1).  
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Table 2.1: Epidemiological and clinical data from the participants used in this study
Cohort name Participant sample name Age in years/Sex CD4 count (cells/µl) Viral load (RNA copies/ml) Clinical 
CT SP1 M 384 49000 HIV positive. Asymptomatic 
SP2  F 327 2772 HIV positive. Asymptomatic 
SP3  M 904 240 HIV positive. Asymptomatic 
SP4  M 1130 <40 HIV positive. Asymptomatic 
SP5  F 511 25500 HIV positive. Asymptomatic 
SP6  M 267 <400 HIV positive. Asymptomatic; ART treatment (Truvada and Efavirenz) 
SP7  M 426 71700 HIV positive. Asymptomatic 
SP8 M 728 <400 HIV positive. Asymptomatic 
SP9 F 1059 52 HIV positive. Asymptomatic 
FV FV2 46/M 159 22900 HIV positive. Asymptomatic. ART naive 
FV3 28/F 101 N/A HIV positive. Oral candidiasis; HSV; retinal necrosis. ART naïve 
FV5 43/M 133 750 000 HIV positive. Previous T.B. ART naïve 
FV6 28/M 187 179 000 HIV positive. Asymptomatic. ART naive 
FV10 32/M 6 750 000 HIV positive. T.B, on T.B treatment. ART naive 
FV11 38/M 124 750 000 HIV positive.Previous TB. ART naïve 
FV14 24/F 16 N/A HIV positive. ART naive 
FV15 33/F 122 343 000 HIV positive. previous TB. ART naive 
FV23 34/F 108 37 000 HIV positive. Asymptomatic. ART naïve 
FV26 49/F N/A N/A HIV positive. Asymptomatic. ART naïve 
FV27 29/F 11 158 000 HIV positive. ART naive 
DR FVDR1 
59/F 
280 64100 Failing first line treatment regimen: Stavudine (d4T), lamivudine (3TC) 
and nevirapine (NVP) or Efavirenz (EFV) 
FVDR4 43/F 54 6700 Failing first line treatment regimen; d4T, 3TC, NVP or EFV 
RES5 27/F 118 353 000 Failing first line treatment regimen; d4T, 3TC, NVP or EFV 
RES6 40/M 53 30800 Failing first line treatment regimen; d4T, 3TC, NVP or EFV 
RES7 41/F 43 74300 Failing first line treatment regimen; d4T, 3TC, NVP or EFV 
RES8 37/F 112 9320 Failing first line treatment regimen; d4T, 3TC, NVP or EFV 
RES10 46/F 57 >750 000 Failing first line treatment regimen; d4T, 3TC, NVP or EFV 
RES12 60/F 301 6680 Failing first line treatment regimen; d4T, 3TC, NVP or EFV 
RES13 N/A N/A N/A Failing first line treatment regimen; d4T, 3TC, NVP or EFV 
RES14 31/F 105 8880 Failing first line treatment regimen; d4T, 3TC, NVP or EFV 
JM TN1 39 660 Below detection Thrombocytopenia 
TN2 20 204 6000 HIV positive. Thrombocytopenia 
TN3 48 155 12565 HIV positive. Thrombocytopenia 
TN4 50 45 94500 HIV positive. Thrombocytopenia, 
TN5 28 N/A N/A HIV positive. Pancytopenia 
TN6 36 101 N/A HIV positive. Rheumatoid arthritis,bicytopenia 
TN7 N/A N/A N/A N/A 
TN8 44 255 Below detection HIV positive 
TN9 39 587 Below detection HIV positive. Bicytopenia 
TN10 25 55 35000 HIV positive. APS, cytopenias 
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2.2 Reagents used throughout the course of this study 
 
2.2.1 Reagents obtained from the NIH AIDS Research and Reference 
Reagents Program 
 
Twelve subtype C and two subtype B envelope glycoprotein (Env) plasmids 
together with a backbone plasmid were obtained from the NIH AIDS Research and 
Reference Reagents Program (Table 2.2). All recombinant plasmids carried 
resistant genes for ampicillin and were expanded by transformation into competent 
Escherichia coli (E. coli) DH5α cells (see section 2.4.1.2). 
 
Human HIV-1 neutralization serum (catalogue number 1984) and Human HIV-1 
negative serum (catalogue number 2411) samples were obtained from the NIH 
AIDS Research and Reference Reagents Program, and reconstituted in 0.25ml 
distilled water for use as controls in the pseudovirion neutralizing antibody assay. 
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Table 2.2: Env plasmids and the backbone vector used for the production of 
pseudoviruses. 
VIRUS NAME CLONING VECTOR SUBTYPE CAT NO DISSOLVED 
IN 
CAP45 pcDNA3.1/V5-
His©TOPO 
C 11316 TE Buffer 
CAP210 pcDNA3.1D/V5-His 
TOPO© 
C 11317 
 
TE Buffer 
ZM53 pCR3.1 C 11313 
 
TE Buffer 
ZM109 pCR3.1 C 11314 TE Buffer 
ZM135 pCR3.1 C 11315 TE Buffer 
ZM197 pCDNA3.1D/V5-His 
TOPO 
C 11309 TE Buffer 
ZM214 pCDNA3.1D/V5-His 
TOPO 
C 11310 TE Buffer 
ZM233 pCDNA3.1D/V5-His 
TOPO 
C 11311 TE Buffer 
ZM249 pcDNA3.1/V5-
His©TOPO 
C 11312 TE Buffer 
Du156 pcDNA3.1/V5-
His©TOPO 
C 11306 TE Buffer 
DU172 pcDNA3.1D/V5-His 
TOPO 
C 11307 TE Buffer 
DU422 pcDNA3.1D/V5-His 
TOPO© 
C 11308 
 
TE Buffer 
B15 pcDNA3.1(+) B 11037 TE Buffer 
B11 pcDNA3.1D/V5-His 
TOPO© 
B 11022 
 
TE Buffer 
pSG3∆env pTZ19U Backbone 
plasmid 
11051 TE Buffer 
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2.2.2 Cell lines 
 
HEK 293T cells and TZM-bl cells were available for use in the laboratory. HEK 
293T cells are derived from human embryonic kidney cells and were used for the 
production of Env-pseudoviruses. The TZM-bl cell line is a HeLa cell clone which 
is engineered to stably express CD4, CCR5 and CXCR4, and was previously 
obtained from the NIH AIDS Research and Reference Reagents Program 
(catalogue number 8129). This cell line also contains a luciferase reporter gene 
that is linked to the HIV-1 LTR region and is under the control of HIV-1 tat. 
Therefore the expression of luciferase is driven by a production HIV-1 infection. 
The TZM-bl cell line was used to measure the neutralizing antibody activity of 
patient plasma/serum in the pseudovirion neutralizing antibody assay.   
 
2.2.3 South African National Blood Services (SANBS) plasma samples 
 
Eighteen HIV-1 seropositive plasma samples were purchased from the SANBS. 
Plasma samples were heat inactivated in a 56°C water bath for an hour and the 
eighteen samples were screened in the pseudovirion neutralizing antibody assay. 
The sample with the best neutralizing antibody activity was subsequently used as 
the positive control throughout the study.  
 
Blanket ethics consent was obtained from the SANBS for the use of the plasma 
samples and therefore no other ethics was required.  
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2.3 Participant sample processing   
 
2.3.1 CT cohort 
 
In order to determine whether optimal results would be obtained from heat 
inactivation of plasma samples, 200µl from each plasma sample was removed and 
stored until used at -80°C. The remaining volumes of plasma were heat inactivated 
(described in section 2.2.3) and stored at -80°C for use in the pseudovirion 
neutralizing antibody assay.   
 
2.3.2 FV cohort and DR cohort 
 
Plasma samples were heat inactivated as previously described in section 2.2.3 
and stored at -80°C until used.   
 
2.3.3 JM cohort 
 
Prior to processing the blood and bone marrow samples, 3 ml of Ficoll-Hypaque 
(Amersham Pharmacia Biotech, Uppsala, Sweden) was added to 15 ml UNI-SEP 
tubes (Novamed, Indiana, USA) and centrifuged at 400xg for one minute at 4°C. 
All patient blood vials were centrifuged at 290xg for 10 minutes at 4°C. During this 
time, sterile cryovials (Nunc, Roskilde, Denmark) were prepared and labelled as: 
serum, EDTAPLASMA, EDTAPBMC and bone marrowPLASMA or bone marrowPBMC. After 
centrifugation, the serum (SST tubes) and plasma (EDTA tubes) portion was 
carefully removed and aliquoted into the relevant cryovials (Nunc). The buffy coat 
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layer from the EDTA tubes was then transferred into a separate 15 ml UNI-SEP 
tube (Novamed) and diluted 1:1 with complete RPMI-1640 media (Appendix B.1.1) 
(Sigma-Aldrich, Missouri, USA) and centrifuged at 1000xg for 20 minutes at 18°C. 
The contents were then transferred into a 15 ml tube (Nunc) and 10 ml of RPMI-
1640 media was added to the contents of the tube (Appendix B.1.1) (Sigma-
Aldrich) and centrifuged at 230xg for 10 minutes at 4°C. The supernatant was 
discarded and the pellet was washed by resuspending in RPMI-1640 media 
(Appendix B.1.1) (Sigma-Aldrich) and recentrifuged. This washing step was 
repeated until the supernatant appeared clear. After the final wash, the 
supernatant was discarded and the pellet was resuspended in 1 ml of freezing mix 
(Appendix B.1.2) and transferred immediately to -80°C until used.  
 
EDTA tubes containing bone marrow aspirates were processed by adding 10 
volumes of RNAlater (Qiagen, Maryland, USA) directly to the blood tube 
containing the bone marrow sample, in order to stabilise the RNA. The samples 
together with the PAXgene blood tubes were then stored at 4°C overnight before 
transferring to -80°C for long term storage.  
 
All serum samples were heat inactivated as described previously in section 2.2.3 
before use in the pseudovirion neutralizing antibody assay.  
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2.4 Pseudovirion neutralizing antibody assay set-up  
 
2.4.1 Preparation of recombinant plasmids  
 
2.4.1.1 Generation of competent E. coli DH5α cells 
 
Competent E. coli DH5α cells were generated under sterile conditions and were 
used in transformation experiments with the 12 subtype C and 2 subtype B Env 
plasmids as well as the backbone plasmid (Table 2.2). Briefly, ten microlitres of E. 
coli DH5α cell stocks (available in the laboratory) were inoculated into 10 ml Luria 
Bertani (LB) broth (Appendix C.1.1) containing no antibiotics and incubated 
overnight in a 37°C shaking incubator. The following day the culture was diluted 
1:40 with fresh LB broth before incubation for 1 hour in a 37°C shaking incubator 
to allow optimal growth to an optical density of 0.4 at 600nm. The culture was then 
centrifuged for 10 minutes at 300xg at 4°C. The supernatant was discarded and 
the pellet was resuspended in 10 ml of ice cold transformation buffer (Appendix 
C.1.2) and transferred immediately on ice for 30 minutes. The reaction was then 
centrifuged for 10 minutes at 300xg at 4°C. Finally, the supernatant was discarded 
and the pellet was resuspended in 1 ml of transformation buffer (Appendix C.1.2). 
The competent E. coli DH5α cells were stored in 100µl aliquots at -80°C until 
used. 
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2.4.1.2 Bacterial transformation of Env and backbone plasmid/s 
 
Twelve subtype C Env plasmids; CAP45, CAP210, ZM53, ZM109, ZM135, ZM197, 
ZM214, ZM233, ZM249, DU156, DU172, DU422, and 2 subtype B Env plasmids, 
SVPB11 and SVPB15 as well as the backbone plasmid pSG∆env (Table 2.2) were 
transformed into competent E. coli DH5α cells. Briefly, 25 µl of competent E. coli 
DH5α cells were added to 5 µl of each Env or backbone plasmid and incubated on 
ice for 30 minutes. The cells were then heat shocked in a 42°C water bath for 90 
seconds and immediately transferred onto ice for 5 minutes. Two hundred 
microlitres of LB broth (Appendix C.1.1) was added to each reaction and incubated 
at 37°C in a shaking incubator for one hour. The backbone plasmid was incubated 
at 34°C to ensure optimal growth. The cells were then spread onto ampicillin 
(Appendix C.1.4) (Roche, Mannheim, Germany) containing agar plates and 
incubated overnight at 37°C in a non shaking incubator for 34°C for the backbone 
plasmid. Successfully transformed E. coli DH5α cells containing the relevant 
plasmid are ampicillin resistant and therefore form colonies on the ampicillin 
contained agar plates. Under sterile conditions, a single colony was picked from 
the ampicillin (Appendix C.1.4) (Roche) containing agar plates and inoculated into 
100 ml LB broth (Appendix C.1.1) containing sterile ampicillin (Appendix C.1.4) 
(Roche). This was incubated overnight at 37°C in a shaking incubator or 34°C for 
the backbone plasmid. 
 
Glycerol stocks were produced for the 14 Env transformed and backbone 
transformed E. coli DH5α cells. Briefly, 200 µl of 100% glycerol (Merck, 
Hohenbrunn, Germany) was gently added to 800 µl of each bacterial culture and 
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stored in sterile cryovials (Nunc) at -80°C until used. The glycerol protects the E. 
coli DH5α cells from damage caused by ice crystals which form in the LB broth 
during freezing.  
 
2.4.1.3 Large scale recombinant plasmid preparations  
 
Plasmid midi preparations were performed on all 14 Env plasmids as well as the 
backbone plasmid as per manufacturer’s instructions (Qiagen). Briefly, each 
recombinant E. coli DH5α culture was inoculated into 100 ml LB broth (Appendix 
C.1.1) and incubated overnight in a dry 37ºC shaking incubator. The bacterial cells 
were then harvested by centrifugation at 6000xg for 15 minutes at 4ºC. The pellet 
was resuspended in 4 ml resuspension buffer P1 containing RNase H (Appendix 
C.1.5.1). Four millilitres of lysis buffer P2 (Appendix C.1.5.2) was then added, 
mixed and incubated at room temperature for 5 minutes to allow for the shearing 
of genomic DNA. During the incubation, the filter cartridge was prepared, by 
screwing the cap onto the nozzle of the QIAfilter midi cartridge and placing the 
cartridge in a convenient tube. Four millilitres of chilled neutralization buffer P3 
(Appendix C.1.5.3) was added and mixed thoroughly. The lysate was then poured 
into the QIAfilter midi cartridge and incubated at room temperature for 10 minutes. 
Four millilitres of equilibration buffer QBT (Appendix C.1.5.4) was added to a 
QIAGEN-TIP 100 and the column was allowed to empty by gravity flow. The cap 
was then removed from the QIAfilter midi cartridge and the plunger was gently 
inserted into the cartridge filtering the cell lysate into the previously equilibrated 
QIAGEN-TIP 100. The cleared lysate was allowed to enter the resin by gravity 
flow. The column was then washed twice with 10 ml of wash buffer QC (Appendix 
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C.1.5.5) and the DNA was eluted with 5 ml of elution buffer QF (Appendix C.1.5.6) 
into a 15 ml tube. The eluted DNA was precipitated by the addition of 3.5 ml room 
temperature isopropanol (Merck) which was mixed and centrifuged at 15000xg for 
30 minutes at 4ºC. The supernatant was discarded and the remaining pellet was 
washed with 2 ml room temperature 70% ethanol (Merck) and centrifuged at 
15000xg for 10 minutes. After discarding the supernatant, the pellet was air dried 
at room temperature for 5 – 10 minutes and redissolved in 150µl distilled water. All 
plasmids were run on a 1% agarose gel (Appendix C.2.3) to verify the presence of 
DNA.   
 
2.4.2 Generation of pseudovirion stocks 
 
2.4.2.1 Mammalian cell lines 
 
HEK 293T and TZM-bl cells were maintained in complete Dulbecco’s Modified 
Eagle Medium (DMEM), containing DMEM (Sigma-Aldrich, Steinheim, Germany), 
10% foetal calf serum (Gibco, Grand Island, USA), L-Glutamine (Gibco), 
penicillin/streptomycin (Sigma-Aldrich) (Appendix B.1.3). All cell lines were 
cultured in 75cm3 flasks and incubated at 37°C in a humidified 5% CO2 incubator. 
 
Cells were trypsinized when confluent, or as needed. The media was discarded 
from the flask, and the cells were rinsed with 5 ml 1X PBS (Sigma-Aldrich). After 
discarding the PBS, 1 ml of 0.25% trypsin/EDTA (Gibco) was added to the cells to 
enable the detachment of the cells from the flask, the cells were incubated at room 
temperature for 30 seconds. The cells were then incubated at 37°C in a 
humidified, 5% CO2 incubator for 2 – 5 minutes before the addition of 10 ml of 
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complete DMEM to inactivate the trypsin and dilute the cells (Appendix B.1.3). The 
cells were detached from the flask by vigorously pipetting the cells and media, and 
diluted as required. 
 
2.4.2.2 HEK 293T cell counting  
 
Cells were counted on a haemocytometer as required. Briefly, freshly trypsinized 
cells were diluted 5 times in 0.4% Trypan blue (Sigma-Aldrich) and loaded onto 
the haemocytometer with a pipette before counting the cells. The average number 
of cells was multiplied by the dilution factor (5) and by the volume of the 
haemocytometer (104) to give the number of cells per ml. 
 
2.4.2.3 HEK 293T cell stocks  
 
Stocks of all cells lines were made by centrifuging freshly trypsinized cells at 200x 
g for 10 minutes at 4°C. The supernatant was discarded and the pellet was 
resuspended in 3 ml freezing mix (Appendix B.1.2) and stored in 1 ml aliquots. 
Cells were slowly frozen to -80°C by transferring them into the Nalgene™ Cryo 
1°C freezing container (Cat# 5100-0001) to achieve a -1°C/min rate of cooling and 
transferred to -80°C for short term storage or liquid nitrogen for long term storage. 
Each time new cell stocks were transferred to the freezing container, the 
isopropanol (Merck) within the container was replaced.     
 
 
62 
 
2.4.2.4 Co-transfection experiments  
 
HEK 293T cells were co-transfected in 25cm3 flasks (Nunc) with the appropriate 
Env plasmid and the backbone plasmid (pSG3∆env) containing all the HIV encoded 
genes, but with a premature stop codon in gp160. HEK 293T cells were cultured 
as described previously. Once the cells reached 70-80% confluency, 1,5x106 HEK 
293T cells were seeded in 25cm3 flasks (Nunc) the day before transfection and 
incubated overnight at 37°C in a humidified, 5% CO2 incubator. After 24 hours, 2µg 
of the appropriate Env plasmid and 2µg of the backbone plasmid (pSG3∆env) was 
added to 100µl of DMEM (no additives). Forty microlitres of transfection reagent 
polyfect® (Qiagen) was added to each reaction, gently mixed and incubated at 
room temperature for 10 minutes. The reaction tube contents were then gently 
added to the 25cm3 flask of HEK 293T cells and incubated for 5 hours at 37°C in a 
humidified, 5% CO2 incubator. After 5 hours, the media was replaced with 
complete DMEM (Appendix B.1.3) and incubated for 48 hours at 37°C in a 
humidified, 5% CO2 incubator.  
 
After 48 hours, the generated pseudoviruses were harvested. Briefly, the content 
of the flasks were transferred into labelled 15 ml tubes (Nunc) and centrifuged at 
400xg at 4°C for 10 minutes. The supernatant containing the pseudovirus was 
filter sterilised (0.22µM Acrodisc® 25mm syringe filters) (Pall Corporation, Ann 
Arbor, USA) with a 10 ml syringe into 15 ml tubes (Nunc) and the pellet was 
discarded. The supernatant was then supplemented with FCS (Gibco) up to a 
concentration of 20% and aliquoted into cryovials (Nunc) and stored at -80°C until 
used.  
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2.4.2.5 TCID50 determination of pseudovirus stocks 
 
The tissue culture infectious dose (TCID50) is defined as the dilution of virus that is 
required to infect 50% of inoculated cell cultures. The TCID50 was determined for 
each pseudovirus stock produced. Briefly, TZM-bl cells were cultured as described 
previously and once 70-80% confluency was reached, 1x105 cells/ml were 
counted. One hundred microlitres of complete DMEM (Appendix B.1.3) was added 
to each well of a 96 well microplate. Twenty five microlitres of pseudovirus was 
added to column 1 (row A-D) and 25µl of a second pseudovirus was added to 
rows E-H. A 5-fold dilution of the pseudoviruses were performed by transferring 
25µl from column 1 to 2, etc and mixing thoroughly each time. Twenty five 
microlitres was discarded from column 11. Column 12 served as the cell control 
(no pseudovirus added). One hundred microlitres of 1x105 TZM-bl cells containing 
a final concentration of 15µg diethylaminoethyl (DEAE) dextran (Sigma-Aldrich) 
was added to each well. The reaction was incubated for 48 hours at 37°C in a 
humidified, 5% CO2 incubator. 
 
After 48 hours, a luciferase assay was performed to detect the reduction in 
luciferase activity, as measured in relative light units, from the TZM-bl cells. The 
reduction in luciferase activity is indicative of viral inhibition by neutralizing 
antibody activity. Briefly, all the media was discarded from the 96 well plates. 
Ninety microlitres of Glo lysis Buffer (Promega, Madison, USA) was added to each 
well and incubated at room temperature for 5 minutes. Fifty microlitres was then 
transferred into the corresponding wells of a white luminometer plate (Promega). 
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Fifty microlitres of BriteGlo reagent (Promega) was then added to each well and 
luciferase activity was measured immediately in a luminometer (Veritas™ 
Microplate Luminometer, Turner Biosystems). 
 
The TCID50 was calculated by the use of a macro obtained from the NIH AIDS 
Research and reference reagent program (http://www.aidsreagent.org). The 
program’s calculation is based on the Reed and Muench equation and is explained 
below (Reed and Muench 1938). 
 
i. Proportionate Distance =  (% mortality at dilution above 50%) – (50%) 
                                      (% mortality at dilution above 50%) – (% mortality at dilution below 
50%) 
 
ii. -Log = dilution above 50% mortality (i.e. 10-3 would be -3) 
 
iii. ((PD)+(-log(dilution factor)) 
 
iv. TCID50 = 10(ii + iii) 
 
 
2.5 Pseudovirion neutralizing antibody assay 
 
Neutralizing antibody assays were performed in 96 well microplates (Nunc). The 
first two columns were used as the cell control (containing no sample and no virus) 
and virus control (containing no sample), respectively. One hundred and fifty 
microlitres of complete DMEM (Appendix B.1.3) was added to the first column (cell 
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control) and 100µl was added to the second column (virus control). For the 4 point 
dilution format (Figure 2.1A), 140 µl of medium was added to rows D and H and 
100 µl was added to the rest of the 96 well microplate. For the eight point dilution 
format 140 µl was added only to row H only (Figure 2.1B). Eleven microlitres of 
heat inactivated sera/plasma was added to the relevant wells in rows D and H (or 
only row H for eight point dilutions) and serially diluted 3-fold by transferring 50 µl 
from row D to C and so on until row A, and from row H to G until row E for the four 
point dilutions and 50 µl was discarded from rows A and E, respectively (whereas 
50 µl was discarded from row A only for the 8 point dilution format). Fifty 
microlitres of the relevant pseudovirus at 4000TCID50 was then added to each well 
on the entire 96 well microplate except the cell control. The reaction was then 
incubated for 1 hour at 37ºC in a humidified 5% CO2 incubator. One hundred 
microlitres of TZM-bl cells (1X105cells/ml) was then added to the entire plate and 
incubated for 48 hours at 37ºC in a humidified 5% CO2 incubator.  
 
After 48 hours the luciferase assay was performed as described previously 
(Section 2.4.2.5). The 4-point dilution format was used to set up and optimize the 
pseudovirion based neutralizing antibody assay using the NIH AIDS Research and 
Reference Reagents Program sera, and SANBS plasma samples. The 
subsequent screening of cohorts was performed using the 8 point dilution format 
(Figure 2.1A and B).  
 
Percentage inhibition was calculated as per the following calculation 
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PERCENTAGE INHIBITION = 
                                                (Virus Control-Cell Control) X 100
(Test Well-Cell Control)
 
The cell control was calculated as the average of the cell control column in RLU 
and the virus control was calculated as the average of the virus control column in 
RLU.s 
 
(A) 
 
(B) 
Figure 2.1: Dilution formats used for pseudovirion neutralizing antibody assay (A) 
Four point dilution (1/20 to 1/540) format used for the set up for the pseudovirion 
based neutralizing antibody assay (B). Eight point dilution (1/20 to 1/43740) format 
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used for the screening of participant samples. The cell control, virus control and 
dilution wells are abbreviated as CC, VC and Dil1 to 4 or 1 to 8, respectively. 
  
2.5.1 Screening of NIH serum and SANBS plasma samples  
 
Plasma is a portion of blood with clotting factors such as fibrinogen which is 
responsible for the coagulation of blood. Serum contains the same components of 
plasma except fibrinogen and other clotting factors. 
 
The positive and negative serum samples (NIH) were screened in the 
pseudovirion neutralizing antibody assay against the subtype C pseudovirus 
CAP210 and the subtype B pseudovirus B15, using the four point dilution format. 
In addition, the 18 seropositive plasma samples (SANBS) and an HIV-1 
seronegative plasma sample (available in our laboratory) were screened in the 
pseudovirion neutralizing antibody assay using the 4 point dilution format against 
CAP210 for the identification of a plasma sample with a greater than average 
breadth of neutralization for use as a positive and negative plasma control.  
 
2.5.2 Testing of participant samples for the presence of neutralizing 
antibodies 
 
2.5.2.1 CT cohort 
 
A pseudovirion neutralizing antibody assay was performed with plasma samples 
SP2 to SP7 with and without heat inactivation to determine which would produce 
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optimal neutralizing antibody results. All plasma samples (SP1 to SP9) were 
subsequently heat inactivated, and screened in the pseudovirus neutralizing 
antibody assay against 5 subtype C and 1 subtype B generated pseudoviruses 
using eight dilutions.  
 
2.5.2.2 FV and DR cohort   
 
Plasma samples from both, the FV and DR cohort, were tested for the presence of 
neutralizing antibodies against the 6 generated subtype C and B pseudoviruses. 
All pseudovirion neutralizing antibody assays were performed using the eight point 
dilution format.  
 
2.5.2.3 JM cohort 
 
The required amount of heat inactivated serum sample aliquots were thawed at 
room temperature and tested for the presence of neutralizing antibodies against 
the 6 generated subtype C and B pseudoviruses. All pseudovirion neutralizing 
antibody assays were performed using the eight point dilution format.
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CHAPTER 3: RESULTS 
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3.1 Study participants’ demographics and clinical data 
 
Epidemiological data of all the participants used in this study are shown in Table 
2.1. From the available clinical data amongst the four cohorts, 12 participants were 
male and 17 were female, ranging from 20 to 60 years of age. The CD4+ T-cell 
counts ranged from 6 to 1130 cells/µl and viral loads ranged from below detection 
to greater than 750 000 RNA copies/ml.  
 
Plasma, serum and peripheral blood mononuclear cells (PBMC’s) were 
successfully obtained from all 10 participants in the JM cohort and bone marrow 
samples were obtained from 8 of the 10 individuals in this cohort. Plasma samples 
from 30 participants in the remaining three cohorts were previously obtained 
during routine diagnosis and were already available for use in the laboratory.  
 
3.2. Preparation of recombinant plasmids for generation of pseudoviruses 
 
 The pSG∆env backbone plasmid and 14 different Env plasmids were all 
successfully transformed into and isolated from E. coli DH5α competent cells 
(Figure 3.1). The DNA concentrations of all 15 purified recombinant plasmids are 
shown in Table 3.1. Isolated plasmids were used to generate pseudovirion stocks.  
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Figure 3.1: Agarose gel electrophoresis (1%) of large scale plasmid preparations 
of the pSG∆env backbone plasmid and 10 different Env plasmids. The 10kb 
molecular weight marker (Fermentas, Ontario, Canada) is shown in Lane 1 and 
the backbone plasmid pSG∆env is illustrated in lane 2. Lanes 3 to 12 include the 
subtype C plasmids CAP210, CAP45, DU156, DU422, ZM53, DU172, ZM197, 
ZM233, ZM109 and the subtype B, B11 plasmid, respectively. 
 
 
 
 
 
 
 
500bp 
3000bp 
1000bp 
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Table 3.1: DNA concentrations of the 14 purified recombinant Env and backbone 
plasmid/s used during the study.    
Plasmid name DNA concentration (ng/µl) 
CAP210 818.1 
CAP45 362.0 
DU156 750.0 
DU422 1119.0 
DU172 1340.1 
ZM214 850.0 
ZM53 251.8 
ZM249 113.3 
ZM109 846.5 
ZM135 371.6 
ZM197 1289.8 
ZM233 230.0 
B15 1356.6 
B11 229.4 
Backbone plasmid (pSG∆env) 938.0 
 
3.3. Generation of pseudoviruses 
 
Co-transfection experiments of each of the Env plasmids together with the pSG∆env 
backbone plasmid in HEK 293T mammalian cell lines, followed by pseudovirion 
infection of TZM-bl cells resulted in the identification of only 6 functional 
pseudoviruses, despite repeated attempts. The tissue culture infectious dose 
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(TCID50) values of all generated pseudoviruses for the TZM-bl cell line are listed in 
Table 3.2. The 6 functional pseudoviruses with a TCID50 greater than 10 000 
included 5 subtype C and 1 subtype B pseudovirus/es (highlighted in yellow in 
Table 3.2) which were subsequently used throughout the course of this study. The 
pseudovirion stocks were depleted or lost infectivity with storage over time, 
therefore the co-transfection experiments and TCID50 determinations were 
repeated as required (see duplicates, and dates prepared in Table 3.2).  
 
Table 3.2: TCID50 values of all pseudoviruses in the TZM-bl cell line.  
 
Pseudovirion name TCID50 Date 
CAP210 
 
91376 17-08-2009 
31250 30-04-2010 
CAP45 
 
10687 09-09-2009 
69877 15-09-2010 
DU156 31250 09-09-2009 
10687 02-08-2010 
DU422 13975 02-09-2009 
69877 02-08-2010 
DU172 2795 18-09-2009 
<50 20-10-2009 
ZM214 <50 18-09-2009 
2795 20-10-2009 
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ZM53 91376 02-09-2009 
349386 28-07-2010 
ZM249 <50 15-07-2009 
<50 02-08-2010 
ZM109 3489 15-07-2009 
699 18-09-2009 
ZM135 <50 15-07-2009 
<50 18-09-2009 
ZM197 559 18-09-2009 
<50 25-09-2009 
ZM233 2795 17-08-2009 
559 24-08-2009 
B15 <50 11-02-2010 
<50 02-08-2010 
B11 53437 11-02-2010 
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3.4 Establishment of the HIV-1 pseudovirion based neutralizing antibody 
assay 
 
Initial attempts to establish the pseudovirion neutralizing antibody assay made use 
of positive and negative serum (NIH) which were tested against the subtype C 
CAP210 and subtype B B15 pseudoviruses (Figure 3.2). The positive serum (NIH) 
did not show promising neutralizing antibody activity against both CAP210 and 
B15, with less than 100% inhibition at the first dilution which rapidly decreased 
with increasing dilutions of the serum (Figure 3.2).  
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Figure 3.2: Percentage inhibition curves for the NIH positive and negative serum 
samples against the subtype C CAP210 and the subtype B B15 pseudoviruses.       
 
Subsequently, 18 plasma samples were purchased from the South African 
National Blood Services (SANBS) and screened against the subtype C CAP210 
pseudovirus for the presence of greater than average neutralizing antibody activity 
in an attempt to identify a positive control. These experiments were set up using 
the 4 point dilution format therefore too few points were available for the 
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determination of IC50 (the concentration of an antibody required for 50% virus 
inhibition) values (Figure 3.3A). 
 
During the initial screening, the negative control plasma showed some degree of 
activity at the lowest dilution ranging from about 50% to 75% inhibition but rapidly 
decreased after the second dilution (Figure 3.3A). Screening of the 18 plasma 
samples led to the identification of three plasma samples (plasma 6, 14 and 16) 
which showed greater than average breadths of neutralization and were 
subsequently retested against CAP210 using 8 dilutions, ranging from 1/20 to 
1/43740 (Figure 3.3B).  
 
 (A) 
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 (B) 
 
 
Figure 3.3: (A) Percentage inhibition curves of 18 plasma samples (SANBS) 
against the subtype C CAP210 pseudovirus. Dilutions ranged from 1/20 to 1/540. 
(B) Percentage inhibition curves for the three plasma samples from A with greater 
than average neutralizing antibody activity were selected for further screening 
against CAP210 using 8 dilutions (1/20 to 1/43740). 
 
Table 3.3: IC50 values for SANBS plasma tested against the CAP210 pseudovirus 
 
Plasma sample number IC50 value 
Plasma 6 33 
Plasma 14 208 
Plasma 16 116 
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Plasma sample 14 showed 100% inhibition at the lowest plasma dilution which 
gradually decreased with increasing dilutions and was subsequently selected as 
the positive control for use in the pseudovirion neutralizing antibody assays 
(Figure 3.3B) and showed the highest IC50 value of 208 (Table 3.3). A 200 ml pack 
of plasma sample 14 was subsequently purchased from the SANBS, heat 
inactivated (described in section 2.2.3) and stored in 100µl aliquots at -80°C until 
required for use. For each experiment a 100µl vial of plasma sample 14 was 
thawed together with a 100µl vial of HIV negative plasma. Any leftover sample was 
subsequently discarded and a fresh vial was thawed for each new experiment.   
 
3.5 Screening of cohorts for the presence of neutralizing antibodies 
 
The 40 patient samples available from the 4 different cohorts (Table 2.1) were 
evaluated against the 5 subtype C and 1 subtype B pseudovirus/es for the 
presence of neutralizing antibodies (highlighted yellow in Table 3.2). Results of all 
percentage inhibition curves are shown in Figures 3.5 to 3.8. 
 
3.5.1 Neutralizing antibody activity within the CT cohort 
 
In order to determine whether optimal results would be obtained from heat 
inactivation of plasma samples or not, a pseudovirion neutralizing antibody assay 
was performed using the SP2 to SP7 samples, with or without heat inactivation 
against the subtype C CAP210 pseudovirion (Figure 3.4A and B). Similar results 
were obtained for both samples,   however since heat inactivated samples are 
more commonly used, in the literature, it was decided that all plasma samples 
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would be heat inactivated before use in the pseudovirion neutralizing antibody 
assay.  
 
 
 
Figure 3.4: (A) Heat inactivated plasma samples SP2 to SP7 tested in the 
pseudovirion neutralizing antibody assay against the subtype C CAP210 
pseudovirus. (B) Plasma samples SP2 to SP7 without heat inactivation, tested 
against the subtype C CAP210 pseudovirus. Dilutions ranged from 1/20 to 
1/43740. 
 
(A) 
(B) 
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Percentage inhibition curves of the 9 slow progressor participants (SP1 to SP9) 
against all 6 pseudoviruses are represented in Figure 3.5A and B. Plasma sample 
SP6 contained the greatest neutralizing antibody activity within the CT cohort 
against CAP210 (Figures 3.4 and 3.5A), maintaining 100% inhibition after the third 
dilution, with the highest recorded IC50 value of 1445 against CAP210 (Table 3.4). 
SP7 was able to maintain 100% inhibition after the second dilution against 
CAP210 (Figure 3.5A) with an IC50 value of 630 (Table 3.4). The CAP45 
pseudovirus was effectively neutralized by SP6 showing a similar percentage 
inhibition curve to that of the positive control (Figure 3.5A) with an IC50 value of 
1202 (Table 3.4). Plasma sample SP7 showed a greater than average 
neutralization breadth against DU156 and showed similar percentage inhibition 
curves to that of SP6, maintaining 100% inhibition at the second dilution (Figure 
3.5A) with high IC50 values of 1737 and 1202, respectively (Table 3.4).  
 
SP6 and SP7 exhibited promising neutralizing antibody activity against DU422 
with IC50 values of 1258 and 724, respectively and SP6 showed the greatest 
neutralizing antibody activity against ZM53 and B11, maintaining 100% inhibition 
at the third dilution with high IC50 values of 1063 and 1096, respectively as shown 
in Figure 3.5B.  
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Figure 3.5: (A) Percentage inhibition curves of plasma samples SP1 to SP9 from 
the CT cohort, with dilutions ranging from 1/20 to 1/43740, against the subtype C 
CAP210, CAP45, DU156 pseudoviruses.   
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Figure 3.5: (B) Percentage inhibition curves for plasma samples SP1 to SP9 from 
the CT cohort, with dilutions ranging from 1/20 to 1/43740,  against the subtype C 
DU422, ZM53 and the subtype B B11 pseudoviruses.  
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3.5.2 Neutralizing antibody activity within the FV cohort 
 
Neutralizing antibody activity from the 11 HIV-1 subtype C infected and 
antiretroviral treatment naïve participants within the FV cohort are shown in 
Figures 3.6A and B against all 6 pseudoviruses. Samples from the FV cohort 
generally did not neutralize CAP210 effectively and the % inhibition (as measured 
in relative light units) rapidly decreased after the first plasma dilution (Figure 3.6A). 
However, FV2 and FV26 showed some degree of neutralization against CAP45 
(Figure 3.6A) with IC50 values of 1000 and 1792, respectively (Table 3.4). DU156 
was effectively neutralized by plasma samples FV5, FV26 and FV27 (Figure 3.6A). 
FV5 and FV26 were able to maintain 100% inhibition after the second plasma 
dilution and FV27 showed a similar percentage inhibition curve to that of the 
positive control. IC50 values obtained for these 3 samples included 1063, 2154 and 
1584, respectively (Table 3.4).  
 
Samples FV14, FV26 and FV27 showed high IC50 values of 1015, 1047 and 4713, 
respectively against DU422 (Figure 3.6B, Table 3.4). Interestingly, plasma 
samples FV2 and FV15 showed neutralization curves that could still inhibit ZM53 
at the second dilution (Figure 3.6B), however these samples revealed low IC50 
values of 541 and 292, respectively (Table 3.4). FV27 was able to neutralize the 
subtype B pseudovirus B11 effectively (Figures 3.6B) with a high IC50 value of 
1634 (Table 3.4).  
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Figure 3.6: (A) Percentage inhibition curves of plasma samples FV2-FV27 from 
the FV cohort, with dilutions ranging from 1/20 to 1/43740, against the subtype C 
CAP210, CAP45, DU156 pseudoviruses. 
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Figure 3.6: (B) Percentage inhibition curves of plasma samples FV2-FV27 from 
the FV cohort, with dilutions ranging from 1/20 to 1/43740, against the subtype C 
DU422, ZM53 and the subtype B B11 pseudoviruses.  
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3.5.3 Neutralizing antibody activity within the DR cohort 
 
Percentage inhibition curves of the 10 HIV-1 subtype C infected participants failing 
first line ARV therapy from the DR cohort against all 6 pseudovirions are illustrated 
in Figure 3.7A and B. FVDR1, RES5, RES6, RES8 and RES10 effectively 
neutralized CAP210 and showed similar percentage inhibition curves and patterns 
of neutralization to one another with high IC50 values of 1792, 1359, 2154, 1318 
and 1737, respectively as shown in (Figure 3.7A and Table 3.4) while plasma 
samples FVDR1, RES8, RES10 and RES12 showed potent neutralizing antibody 
activity against CAP45 showing similar percentage inhibition curves to each other 
(Figure 3.7A) with IC50 values of 2256, 1047, 1934 and 1338, respectively (Table 
3.4). In contrast, RES7, RES13 and RES14 showed little or no neutralizing 
antibody activity against CAP45 (Figure 3.7A). DU156 was effectively inhibited by 
FVDR1, RES5, RES6, RES8 and RES10 (Figure 3.7A) with the plasma samples 
maintaining 100% inhibition after the third dilution with high IC50 values of 3066, 
1015, 2326, 2796 and 1995, respectively (Table 3.4). FVDR1, RES5, RES6 and 
RES10 exhibited potent neutralization against DU422 (Figure 3.7B) maintaining 
100% inhibition by the fourth plasma dilution and high IC50 values were obtained 
for these samples of 2796, 1423 and 1609, respectively. FVDR1, RES5, RES6, 
RES10 and RES8 was effective at inhibiting ZM53 with FVDR1 maintaining 100% 
inhibition by the fourth dilution and the others maintaining 100% inhibition at the 
third dilution (Figure 3.7B). B11 was successfully inhibited by FVDR1, RES6, 
RES8 and RES10, and all maintained 100% inhibition at the third plasma dilution 
(Figure 3.7B) with IC50 values of 2590, 1063, 2221, 2026 and 2363 respectively 
(Table 3.4).      
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Figure 3.7: (A) Percentage inhibition curves of plasma samples FVDR1 to RES14 
from the DR cohort, with dilutions ranging from 1/20 to 1/43740, against the 
subtype C CAP210, CAP45, DU156 pseudoviruses. 
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Figure 3.7: (B) Percentage inhibition curves of plasma samples FVDR1 to RES14 
from the DR cohort, with dilutions ranging from 1/20 to 1/43740, against the 
subtype C DU422, ZM53 and the subtype B B11 pseudoviruses. 
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3.5.4 Neutralizing antibody activity within the JM cohort 
 
Neutralization activities of the 10 seropositive or seronegative participants with 
autoimmune diseases from the JM cohort were evaluated against all 6 
pseudoviruses and are represented in Figure 3.8A and B. The calculated IC50 
values are listed in Table 3.4. 
  
The relative light units (RLU) measured for sera TN1, TN2, TN3 and TN7 showed 
less than 50% inhibition against CAP210, CAP45, Du156, Du422 and ZM53 at the 
first dilution indicative of little or no neutralizing antibody activity (Figure 3.8A to 
Figure 3.8B) therefore IC50 values could not be obtained for these samples. TN8 
and TN10 exhibited potent neutralizing antibody responses against the CAP210 
(Figure 3.8A) with IC50 values of 1584 and 831, respectively (Table 3.4). Similarly, 
TN6 showed promising neutralizing antibody activity against CAP210 with 100% 
inhibition observed at the fourth dilution and the highest IC50 value of 3414 (Table 
3.4). In addition, TN6 showed a similar percentage inhibition curve to the positive 
control against CAP45 (Figure 3.8A) with an IC50 of 4105 (Table 3.4). Serum 
sample TN5 showed a greater than average breadth of neutralization against 
DU156 maintaining almost 100% inhibition at the third dilution with an IC50 of 4105 
(Table 3.4). In addition, TN6 also showed potent neutralizing antibody activity 
against DU156 with almost 100% inhibition at the fourth dilution (Figure 3.8A). 
DU422 was most potently neutralized by TN6 (Figure 3.8B) with the highest IC50 
value of 13594, TN5 and TN8 also showed greater than average neutralizing 
antibody activity against DU422 (Figure 3.8B) with IC50 values of 1239 and 1634 
respectively (Table 3.4).  
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TN5, TN6, TN8 and TN10 showed neutralizing antibody activity greater than the 
positive control against ZM53 (Figure 3.8B). TN6 had the highest IC50 value of 
2590 against ZM53, together with TN5 and TN8 with IC50 values of 2026 and 1685 
respectively whereas TN10 showed an IC50 value of 363 (Table 3.4).  
 
B11 was effectively neutralized by, maintaining 100% inhibition at the third dilution 
with an IC50 value of 2590 (Table 3.4). TN2, TN5, TN8, TN9 and TN10 showed 
greater antibody neutralization activity compared to the positive control. TN1, TN3 
and TN7 showed little or no neutralizing antibody activity against B11.  
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Figure 3.8: (A) Percentage inhibition curves of sera TN1 to TN10 from the JM 
cohort, with dilutions ranging from 1/20 to 1/43740, against the subtype C 
CAP210, CAP45, DU156 pseudoviruses. 
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Figure 3.8: (B) Percentage inhibition curves of sera TN1 to TN10 from the JM 
cohort, with dilutions ranging from 1/20 to 1/43740, against the subtype C DU422, 
ZM53 and the subtype B B11 pseudoviruses.  
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Table 3.4: IC50 values of 40 patient samples from four different cohorts against 6 
pseudoviruses in a neutralizing antibody assay.   
PATIENT 
COHORT 
CAP210 CAP45 DU156 DU422 ZM53 B11 
CT       
Positive 
control 
292 1278 259 2786 106 116 
SP1 331 302 127 212 163 57 
SP2 131 341 65 138 215 59 
SP3 113 184 179 297 85 85 
SP4 259 50 179 122 140 45 
SP5 116 78 558 187 267 153 
SP6 1445 1202 1202 1258 1063 1096 
SP7 630 423 1737 724 67 243 
SP8 131 n/a 163 50 78 71 
SP9 140 27 109 255 179 47 
FV       
Positive 
control 
153 650 243 558 47 78 
FV2 363 1000 251 392 541 196 
FV3 363 222 168 45 91 190 
FV5 229 120 1063 176 50 100 
FV6 179 65 321 142 179 31 
FV10 106 59 158 501 52 33 
FV11 131 190 149 146 65 36 
FV14 650 363 229 1015 88 35 
FV15 575 611 158 404 292 35 
FV23 222 558 410 486 267 37 
FV26 113 1792 2154 1047 478 423 
FV27 630 508 1584 4713 131 1634 
DR       
Positive 
control 
311 1015 14678 306 95 83 
FVDR1 1792 2256 3066 2796 3920 2590 
FVDR4 208 27 87 122 92.6 88 
RES5 1359 621 1015 844 1187 1063 
RES6 2154 984 2326 1423 1934 2221 
RES7 153 66 416 56 133.86 386 
RES8 1318 1047 2796 39 1659 2026 
RES10 1737 1934 1995 1609 1560 2363 
RES12 292 1338 660 471 346.74 450 
RES13 208 n/a 51 35 247.36 691 
RES14 222 n/a 38 n/a 107.98 423 
JM       
Positive 
control 
311 3981 n/a 1537 386 127 
TN1 20.2 36 41 40 23 18 
TN2 n/a 35 45 62 22 316 
TN3 n/a 27 19 51 33 23 
TN4 109 104 416 81 28 21 
TN5 2026 2435 4105 1239 2026 1685 
TN6 3414 4105 n/a 13594 2590 2590 
TN7 n/a 23 n/a n/a 20 21 
TN8 1584 2290 1239 1634 1685 1584 
TN9 123 275 229 236 57 85.7 
TN10 831 857 691 423 363 386 
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Overall, the negative control showed some non-specific neutralization activity from 
approximately 50% at the first/lowest dilution which rapidly decreased by the 
second and higher dilutions (Figures 3.4 to 3.8). Neutralizing antibody activity of 
the positive control was comparable amongst the JM and CT cohorts, showing 
high IC50 values and good activity against the subtype C CAP45 and DU422 
pseudoviruses (Table 3.4). However the activity of the positive control was not 
comparable amongst the FV and DR cohort. No promising neutralization was 
observed against the FV cohort however CAP45 and DU156 were effectively 
neutralized by the positive control in the DR cohort (Table 3.4).  
In summary, plasma sample SP6 contained promising neutralizing antibody 
activity with the ability to neutralize all 5 subtype C and 1 subtype B 
pseudovirus/es with the highest IC50 values among the slow progressor 
participants in the CT cohort. Although the FV cohort did not include any plasma 
samples that could neutralize all 6 pseudoviruses, FV26 and FV27 effectively 
neutralized 3 of the 6 pseudoviruses. The DR cohort included 5 plasma samples 
with a greater than average breadth of neutralization. FVDR1 and RES10 
effectively neutralized all 6 pseudoviruses, RES6 and RES8 neutralized 5 of the 6 
pseudoviruses and RES5 neutralized 4 of the 6 pseudoviruses. The serum 
samples with the best neutralizing antibody activity in the JM cohort included TN5, 
TN6 and TN8 (Table 3.4) which were effectively able to neutralize all 6 
pseudoviruses.    
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CHAPTER 4: DISCUSSION 
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Humoral immunity involves antibody protection against pathogens and subsequent 
neutralization of pathogens in the body. Most HIV-1 infected individuals produce 
an autologous neutralizing antibody response during the first year of infection 
however such antibodies lag behind viral escape mechanisms. One of the major 
goals for an effective HIV-1 vaccine is to elicit an appropriate cross reactive or 
broadly neutralizing antibody response capable of controlling infection. To date, 
only a handful of broadly neutralizing antibodies have been identified which are 
produced in the minority of infected individuals, illustrating the poor 
immunogenicity of neutralizing antibody epitopes (Binley 2009). Interestingly some 
HIV-1 infected individuals develop cross reactive neutralizing antibody responses. 
Further analysis of such patients provides insight into conditions that favour the 
production of broadly neutralizing antibodies that could be useful for vaccine 
development.  In this study we screened plasma or serum samples from four 
different cohorts for the presence of greater than average neutralization breadths 
against a panel of 5 subtype C and 1 subtype B Env-pseudoviruses.  
 
4.1 Generation of Env-pseudoviruses 
 
Twelve subtype C and 2 subtype B Env-pseudoviruses were generated for use in 
the pseudovirion neutralizing antibody assay which was used to screen plasma or 
serum from four different patient cohorts for the presence of HIV-1 specific 
neutralizing antibodies. Six pseudoviruses were functional and showed a TCID50 
greater than 10 000 which were subsequently used throughout the study. These 
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included 5 subtype C pseudoviruses, CAP210, CAP45, DU156, DU422, ZM53 and 
1 subtype B pseudovirus, B11 (Table 3.2).  
The subtype C Env-pseudoviruses mentioned above are included in a South 
African subtype C Env-pseudovirus panel (Li, Salazar-Gonzalez et al. 2006). A 
similar Env panel was developed with subtype B pseudoviruses, of which B11 was 
included (Li, Gao et al. 2005). Clinical and geographic information is available for 
all Env isolates used. Env clones with the CAP prefix were isolated from 
participants in Durban enrolled in a study of acute or early HIV transmission 
organized by the Center for the AIDS Program of Research in South Africa 
(CAPRISA) in 2005 (Li, Salazar-Gonzalez et al. 2006). The CAP210 Env was 
isolated 5 weeks after the estimated infection date from an individual with a viral 
load of 127 000 RNA copies/ml and a CD4 count of 461 cells/µl and CAP45 was 
also isolated 5 weeks after the estimated infection date from a participant with a 
viral load of 236 000 RNA copies/ml and a CD4 count of 974 cells/µl. Env clones 
with a DU prefix were obtained from commercial sex workers at truck stops 
between Durban and Johannesburg (Li, Salazar-Gonzalez et al. 2006). The 
participant from which DU156 Env was obtained showed a viral load of 22 122 
RNA copies/ml and a CD4 count of 404 cells/µl. The DU156 Env was isolated in 
1999 less than 4 weeks after the patient’s estimated infection date. DU422 was 
isolated in 1998, 8 weeks after the estimated infection date from a patient with a 
viral load of 17 118 RNA copies/ml and a CD4 count of 409 cells/µl. The ZM53 
Env clone was obtained from a participant involved in a study of HIV-1 discordant 
couples in Lusaka, Zambia. The Env was isolated in 2000, less than 14 weeks 
after the estimated date of infection. This participant showed a viral load of 26 643 
RNA copies/ml, the CD4 count was not available (Li, Salazar-Gonzalez et al. 
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2006). The subtype B pseudovirus, B11 (also known as PVO4) was isolated in 
1996 from a patient in Italy who had been infected for 4 weeks prior to the 
collection of Env. The patient had a viral load of 2 127 976 RNA copies/ml and a 
CD4 count of 311 cells/µl (Li, Gao et al. 2005). All Env isolates were R5-tropic.  
 
Recently, Seaman et al. (2010) assembled a panel of 109 Env-pseudoviruses 
representing a diverse range of isolates to allow for the systemic characterization 
of neutralizing antibody responses elicited by vaccine immunogens. All major 
subtypes were included; Envs from post-transmission, early and chronic phases of 
infection as well as geographically diverse Envs were also included in the panel. 
HIV-1 positive plasma samples were pooled together to assess the sensitivity of 
the generated pseudoviruses. All pseudoviruses were classified as either Tier 1A 
(very high sensitivity to neutralization), Tier 1B (above average neutralization 
sensitivity), Tier 2 (moderate neutralization sensitivity) and Tier 3 (low 
neutralization sensitivity). According to this classification, all the subtype C 
generated pseudoviruses used in our study were classified as Tier 2 (Seaman, 
Janes et al. 2010).     
 
Another study screened 24 plasma samples from patients with broadly neutralizing 
antibody activity (Binley, Lybarger et al. 2008). The plasma samples were 
screened in a TZM-bl pseudovirion based neutralizing antibody assay against a 
panel of 17 subtype C and 20 subtype B pseudoviruses to confirm cross reactivity. 
Pseudoviruses were categorised according to neutralization susceptibility. Among 
other pseudoviruses generated, CAP45, CAP210, DU156, DU422 and ZM53 were 
included in their subtype C panel. According to the results of their study, CAP45 
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was most sensitive to neutralization followed by DU156. CAP210 was moderately 
neutralized by the plasma samples whereas ZM53 and DU422 were quite resistant 
to neutralization by plasma samples. They also noted that the subtype B infected 
plasma samples were not able to neutralize the Durban subtype C pseudoviruses, 
including DU156 and DU422 as effectively as the other subtype C pseudoviruses. 
By contrast, subtype C infected plasmas were able to neutralize the Durban as 
well as other subtype C pseudoviruses with no difference in neutralization capacity 
(Binley, Lybarger et al. 2008). Another study evaluated the neutralization profiles 
of 70 plasma samples from HIV-1 chronically infected individuals (Gray, Taylor et 
al. 2009). According to their results, CAP210 was the least sensitive to 
neutralization and CAP45 showed moderate neutralization sensitivity with DU156 
being among the pseudoviruses most sensitive to neutralization (Gray, Taylor et 
al. 2009). The results of our study are similar to that Gray et al; our data reveal 
that DU156 was most sensitive to neutralization. In total, 12 out of 40 participant 
samples were able to effectively neutralize DU156. While CAP45, DU422 and B11 
showed moderate neutralization sensitivity, with 10 samples neutralizing these 
pseudoviruses with high titers. CAP210 and ZM53 were the least sensitive to 
neutralization in this study, neutralized by only 9 samples. However, the 
neutralization sensitivity differed within cohorts. For example, within the CT cohort, 
only 2 out of 9 plasma samples were able to neutralize DU156 whereas only 1 
sample neutralized the remaining pseudoviruses. DU156 and DU422 were most 
easily neutralized within the FV cohort, effectively neutralizing 3 out of 11 plasma 
samples. Within the DR cohort, 5 out of 10 plasma samples neutralized CAP210, 
DU156, ZM53 and B11 and within the JM cohort, 3 samples were effectively able 
to neutralize all 6 pseudoviruses. 
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4.2 Establishment of the HIV-1 pseudovirion based neutralizing antibody 
assay 
 
A standardized and reproducible neutralizing antibody assay for the measurement 
of neutralizing antibodies is needed for the accurate comparison of antibody 
responses against a panel of diverse viral strains among different laboratories 
(Polonis, Brown et al. 2008). Two types of neutralizing antibody assays are 
currently used which make use of virus propagated in peripheral blood 
mononuclear cells (PBMC) or viruses produced by pseudotyping (Polonis, Brown 
et al. 2008). Viruses derived from PBMC’s represent a heterogeneous viral 
population since the viruses use the error prone reverse transcriptase to replicate. 
By contrast, pseudoviruses are derived from co-infection of HEK 293T cells with a 
DNA plasmid encoding the HIV genome lacking the Env component together with 
an Env-encoding plasmid from a strain of choice. Pseudoviruses allow for the 
production of a homogeneous viral population with only one Env strain 
incorporated. Pseudotyped viruses are used to infect TZM-bl cells whereas PBMC 
derived viruses are used to infect PBMC’s (Polonis, Brown et al. 2008). The 
pseudovirion neutralizing antibody assay is advantageous because it reduces 
variables such as viral growth kinetics or other non-antibody related factors which 
may influence the results, however this assay format has concerns regarding the 
reproducibility of results. Although the PBMC based neutralizing antibody assay is 
a better representation of natural infection, this assay format shows variation in 
results possibly due the genetic variability from different PBMC donors (Mascola, 
D'Souza et al. 2005; Polonis, Brown et al. 2008). 
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Eighteen plasma samples (SANBS) were purchased for the set up of the 
pseudovirion neutralizing antibody assay. Plasma sample 14 which was selected 
as the positive control for this study did not show reproducible results throughout 
all pseudovirion neutralizing antibody experiments due to variations in the assay, 
as noted by other researchers (Mascola, D'Souza et al. 2005; Polonis, Brown et al. 
2008). However, the negative control plasma was fairly consistent and did not 
exceed 50% inhibition at the first dilution and rapidly decreased by the second 
dilution (Figures 3.4 to 3.8). 
 
4.3 CT Cohort 
 
Slow progressors are of great interest because they may provide information 
about HIV control mechanisms which could be used for vaccine design and 
development. However, the role of neutralizing antibodies in delayed disease 
progression among these individuals is controversial. Several studies have 
implicated the cellular immune system, in particular CD8+ cytotoxic T lymphocytes 
as a major contributor in the control of HIV-1 infection among slow progressors 
(Ogg, Kostense et al. 1999; Gillespie, Kaul et al. 2002). In addition, the major 
histocompatibility complex (MHC) class I allele HLAB*57 is found to be over 
represented in these individuals (Costello, Tang et al. 1999; Gillespie, Kaul et al. 
2002; Altfeld, Addo et al. 2003). MHC class I molecules are involved in interactions 
with CD8+ cytotoxic T-lymphocytes to initiate killing of infected cells. By contrast, 
little or no role for the humoral immune response has been reported in patients 
with slow disease progression (Zwart, van der Hoek et al. 1994; Cecilia, 
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Kleeberger et al. 1999). Cecilia et al. (1999) evaluated neutralizing antibody 
responses in rapid progressors and long term non progressors (LTNP). Their 
results showed no significant differences in neutralizing antibody titers against 
primary HIV-1 isolates during early infection (when both groups were 
asymptomatic). Alternatively, at a later time point (when rapid progressors showed 
signs of clinical AIDS), long term non progressors exhibited increased neutralizing 
antibody titers whereas rapid progressors showed decreased neutralizing antibody 
levels. Another study by Zwart et al. (1994) studied the rate of disease progression 
after seroconversion and the level of IgG antibody responses in a group of rapid 
progressors and slow progressors. No significant difference was observed in 
neutralizing antibody responses against Env epitopes between the two groups. 
However more vigorous neutralizing antibody responses against the V3 domain 
and gp41 epitopes were observed in rapid progressors a few months after 
seroconversion. A study by Doria-Rose et al. (2009) also showed that there was 
no significant different between the neutralizing antibody responses of progressors 
and slow progressors. In their study, serum samples were screened from three 
cohorts, long term non progressors, slow progressors and progressors, for the 
presence of broadly neutralizing antibodies. Their results revealed that 
progressors had the highest titer (42%) of broadly neutralizing antibody responses 
against a panel of 5 Env-pseudotyped viruses and among the slow progressor 
cohort, 41% of the samples showed broadly neutralizing antibodies. Long term 
non progressors showed the lowest titre (25%) of broadly neutralizing antibodies. 
The progressor and slow progressor cohorts did not differ significantly in the 
proportion of patients with good neutralization breadth (Doria-Rose, Klein et al. 
2009). This suggests that neutralizing antibodies play a little role in the delayed 
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disease progression evident among slow progressors (Altfeld, Addo et al. 2003; 
Bailey, Lassen et al. 2006; Euler, van Gils et al. 2010). By contrast, other studies 
claim that neutralizing antibodies may play a significant role in viral control. 
Montefiori et al. (1996) evaluated the serum from LTNP and progressors for the 
presence of neutralizing antibodies and infection enhancement. Their results 
revealed that LTNP had significantly higher neutralizing antibody titers when 
compared to progressors. Similarly another study showed that LTNP exhibited 
strong neutralizing antibody response against a diverse panel of primary isolates 
(Cao, Qin et al. 1995). 
 
The above studies highlight the controversy around the role of neutralizing 
antibodies in individuals with slow disease progression. In this study, we evaluated 
the presence of neutralizing antibodies in participants with slow disease 
progression. Our results revealed 2 plasma samples (SP6 and SP7) with 
exceptionally good neutralizing antibody activity against a panel of 6 
pseudoviruses (5 subtype C and 1 subtype B). The remaining 7 samples did not 
harbour a greater than average breadth of neutralizing antibodies. SP6 was able 
to neutralizing all 6 generated pseudoviruses with high neutralizing antibody titers. 
From the available clinical data, SP6 showed a CD4 T-cell count of 267 cells/µl 
and a viral load of below 400 RNA copies/ml. At the time of sample collection, no 
other clinical data was available, but it was determined that patient SP6 was on 
antiretroviral treatment at the time of sample collection (Truvada and Efavirenz), 
which could account for the higher neutralization detected (see below). No clinical 
symptoms of AIDS were reported. 
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SP7 showed promising percentage inhibition curves against 3 subtype C 
pseudoviruses (CAP210, DU156 and DU422) with a high IC50 value obtained for 
DU156 (1737) only. Clinical data revealed that SP7 was asymptomatic at the time 
of sample collection with a CD4 count of 426 cells/µl and a viral load of 71700 
RNA copies/ml. Thus SP7 is a promising candidate for further evaluation and 
characterization of their neutralizing antibody responses.  
 
The potent neutralization activity of SP6 may be attributed to the ARV treatment. 
There is evidence of immune reconstitution in patients undergoing treatment with 
HAART (Gulick, Mellors et al. 1997). Among patients who initiate HAART therapy 
during chronic infection, it has been documented that there is an increase or 
reconstitution of neutralizing antibody responses (Gulick, Mellors et al. 1997). This 
is supported by findings which demonstrated that spontaneous reconstitution of 
neutralizing antibody responses were observed in 4 out of 19 chronically HIV-1 
infected patients undergoing HAART therapy (Kimura, Yoshimura et al. 2002).  
 
Possible mechanisms for the delayed disease progression in the remaining 7 
subjects may include host genetic factors such as polymorphisms in their HLA or 
chemokine receptors or infection with attenuated viruses such as nef- defective 
particles associated with slow progression as well as strong CD8+ cytotoxic T 
lymphocyte responses (Dyer, Zaunders et al. 2008). In addition, structural 
observations have been made about the length of the variable loops among slow 
progressors. The length of the variable loops on the Env appears to correlate with 
antibody escape; longer loop lengths are associated with escape from antibody 
recognition (Gray, Moore et al. 2007). Interestingly, the V1V2 loop lengths are 
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shorter in HIV controllers than in non controllers during early and chronic infection 
(Sagar, Wu et al. 2006). The number of N-linked glycosylation sites on the surface 
of gp120 correlates with viral escape from immune recognition and HIV controllers 
were found to have a significantly lower number of potential N-linked glycosylation 
sites compared to non controllers, suggesting that viral adaptive escape 
mechanisms are limited in these individuals (Sagar, Wu et al. 2006; Gray, Moore 
et al. 2007). In addition, Bello et al. (2005) found that the rate of viral evolution 
tends to be much lower in slow progressors compared to progressors, similarly the 
diversity of the virus emerged at a much lower rate in patients who could control 
HIV infection compared to non controllers. 
 
Van Gils et al. (2009) studied 35 subjects in the Amsterdam cohort, comprising 20 
long term non progressors and 15 progressors for the presence of cross reactive 
neutralizing antibodies against subtype A, B, C and D pseudoviruses at 2 and 4 
years post-seroconversion. This study concluded that 2 years after seroconversion 
20% of the subjects had developed cross reactive neutralizing antibody responses 
and this figure increased to 31% 4 years after seroconversion. They also revealed 
that high viral loads and low CD4 counts were associated with early development 
of cross reactive neutralizing antibodies and neutralizing antibody titers were 
shown to increase during the course of infection in 91% of the participants (van 
Gils, Euler et al. 2009). Importantly, this study concluded that no significant 
differences were observed in neutralizing antibody serum activity between long 
term non progressors and progressors.  
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According to the results of this study, no direct correlation can be made between 
the presence of neutralizing antibodies and slow disease progression. Although 
one sample (SP6) was identified with exceptionally broad neutralizing antibodies, 
further studies are required to confirm that the ARV treatment is not contributing to 
the overall measured neutralization effect.  
 
4.4 FV cohort 
 
Eleven HIV-1 subtype C infected patients who were naive to ARV treatment were 
included in the FV cohort. Screening of the 11 plasma samples for the presence of 
neutralizing antibodies revealed several patients with moderate neutralization 
capacity against a panel of 6 pseudoviruses. FV26 exhibited greater than average 
breadths of neutralization against 3 subtype C pseudoviruses (CAP45, DU156 and 
DU422). Unfortunately no clinical data was available for this patient. FV27 in 
particular, is of special interest with its ability to effectively neutralize the subtype B 
pseudovirus, B11 as well as the subtype C pseudoviruses, DU156 and DU422, 
suggesting that FV27 contains cross reactive neutralizing antibodies against 
subtypes B and C isolates. Interestingly, this patient has a very low CD4 T-cell 
count of 11 cells/µl and a viral load of 158 000 RNA copies/ml. Plasma sample 
FV14 also had a very low CD4 T-cell count of 16 cells/µl but the viral load was not 
available. This patient showed neutralizing antibodies capable of inhibiting the 
subtype C pseudovirus DU422.  
 
Patient plasma sample FV2 had a CD4 T-cell count of 159 cells/µl and a viral load 
of 22900 RNA copies/ml. This patient was able to neutralize 2 subtype C 
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pseudoviruses (CAP45 and ZM53) with moderate neutralization breadth.  FV5 
showed a very high viral load of 750 000 RNA copies/ml and a CD4 T-cell count of 
133 cells/µl, FV5 was able to neutralize one subtype C pseudovirus (DU156) with 
a greater than average breadth of neutralization.  
 
Consistent with the data obtained by van Gils et al. (2009), the results of our study 
show that patients with exceptionally low CD4 T-cell counts (FV14 and FV27) can 
exhibit potent neutralizing antibodies capable of neutralizing subtype C as well as 
subtype B (plasma samples FV27) isolates.  
 
Kelly et al. (2005) evaluated the neutralizing antibody patterns and viral escape in 
10 HIV-1 chronically infected patients with non-B subtypes. All patients included in 
the study were ARV treatment naive. Their results revealed that all 10 subjects 
had autologous neutralizing antibodies that could neutralize virus obtained 6 
months earlier but not later time point viruses. However this study used primary 
virus rather than pseudoviruses and it has been documented that primary viruses 
are generally more difficult to neutralize than pseudovirus (Moore, Cao et al. 
1995). 
 
Devito et al. (2006) evaluated the autologous and heterologous neutralizing 
antibody responses before and during ARV treatment of 6 subjects. Before the 
initiation of ARV treatment, the subjects had viral loads ranging from 70 000 to 800 
000 RNA copies/ml and CD4 counts ranging from 20 to 360 cells/µl. Before ARV 
treatment, results revealed that all subjects showed very little and weak 
autologous neutralizing antibody responses ranging from 0 to 38% as well as 
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weak heterologous neutralizing antibody responses. Patients designated A, B and 
C neutralized 3, 2 and 1 out of 8 heterologous viruses respectively before 
antiretroviral treatment was initiated. These patients had all had low CD4 counts 
and high viral loads. Patient A had a very low CD4 count of 20 cells/µl and a viral 
load of 70 000 RNA copies/ml. Patient B had a CD4 T-cell count of 110 cells/µl 
with a very high viral load of 800 000 RNA copies/ml and patient C and a CD4 
count of 80 cells/µl with a viral load of 70 000 RNA copies/ml (Devito, Hejdeman et 
al. 2006). ARV treatment was initiated for a 12 to 19 month period and serum 
samples were subsequently re-analysed for neutralization activity. Results post-
treatment revealed no significant improvement in autologous or heterologous 
neutralizing antibody responses despite successful ARV treatment and increased 
CD4 counts (Devito, Hejdeman et al. 2006). The data obtained from this study 
before treatment are consistent with our data, in that generally weak neutralization 
responses were observed within the FV cohort and the subjects with very low CD4 
counts and very high viral loads exhibited greater than average neutralizing 
antibody activity.  
 
Consistent with some of the literature (Zwart, van der Hoek et al. 1994; Cecilia, 
Kleeberger et al. 1999; Doria-Rose, Klein et al. 2009), the neutralizing antibody 
responses between patients with slow disease progression and patients with AIDS 
were similar. The CT cohort revealed 2 samples (SP6 and SP7) with 1 (SP6) 
sample that exhibited potent neutralization breadth against 6 pseudoviruses and 
the FV cohort revealed 2 (FV26 and FV27) with greater than average breadth of 
neutralization against 3 pseudoviruses. This suggests that neutralizing antibodies 
may be a poor predictor of disease progression.  
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4.5 DR cohort 
 
The use of antiretroviral therapy (ART) has transformed the management of HIV-1.  
However, one of the major challenges with ART is that prolonged use or non-
adherence can lead to virus escape mutants who are no longer susceptible to the 
drug and so drug resistance develops (Menendez-Arias 2002). Studies have found 
that certain mutations conferring drug resistance in viruses may be considered 
favourable in some cases, providing new ways to target the virus by increasing 
susceptibility to neutralizing antibodies (Reeves, Lee et al. 2005; Hu, Mahmood et 
al. 2007). Certain mutations may occur in the N-linked glycosylation sites of gp120 
rendering the virus more susceptible to neutralization by the broadly neutralizing 
antibody 2G12 (Hu, Mahmood et al. 2007). A recent study demonstrated that a 
virus strain resistant to an anti-HIV agent cyclotriazadisulfonamide (CADA), 
targeting the CD4 region of gp120 showed increased sensitivity to the 2G12 
neutralizing antibody as well as soluble CD4 (Vermeire, Van Laethem et al. 2009). 
This study found that anti-CD4 monoclonal antibodies bound more efficiently to the 
CADA escape mutant compared to the wild type isolates. In the case of the CADA 
resistant gp120, the escape mutations involved the reduction of N-linked 
glycosylation sites on gp120 which rendered the virus more susceptible to 
neutralization by neutralizing antibodies (Vermeire, Van Laethem et al. 2009).  
 
In order to evaluate the neutralizing antibody profiles of treatment experienced 
patients failing therapy, we screened 10 plasma samples from HIV-1 subtype C 
infected individuals who were treatment experienced and failing their first line 
treatment regimen for the presence of neutralizing antibodies.  
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Our results revealed 5 plasma samples with exceptionally good neutralizing 
antibody responses, these included plasma samples FVDR1, RES5, RES6, RES8 
and RES10. Interestingly, 4 out 5 samples (FVDR1, RES6, RES8 and RES10) 
showed promising neutralizing antibody activity against the subtype B, B11 as well 
as subtype C pseudoviruses. This implies that these participants may contain 
cross reactive neutralizing antibodies in their plasma or that the ARV treatment 
played a role in the potent neutralization breadths of these individuals. The above 
plasma samples all showed common clinical data, with low CD4 counts and high 
viral loads. However this was not unique among samples which exhibited good 
neutralization activity since low CD4 counts and high viral loads are usually 
expected among individuals who are failing ARV therapy. Therefore no conclusion 
can be drawn from the clinical data of these individuals. The presence of ARV 
drugs in the plasma of these individuals may have contributed to some extent to 
the measured neutralization. This may have occurred through the carry over of 
any ARV drugs present in the plasma to the pseudovirion neutralizing antibody 
assay (Dreyer, Kallas et al. 1999).  
 
The effect of HAART on the humoral immune response to HIV-1 was evaluated by 
Binley et al. (2000). They concluded that when HAART is initiated during acute 
infection, the humoral response to HIV-1 is suppressed. They also argued that 
when HAART is initiated after several years of infection, it has little effect on 
neutralizing antibody responses. Morris et al. (2001) performed a longitudinal 
study, evaluating the humoral immune responses in 19 chronically infected 
patients. The patients were categorised into 2 groups, HAART successes (viral 
load of <500 RNA copies/ml within 12 weeks of therapy and continued 
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suppression for 1 year) and HAART failures (less than 10 fold decrease in viral 
load within 1 year on HAART). They collected plasma samples before and 1 year 
after initiation of HAART. Their results before therapy revealed that neutralizing 
antibody titers against the HIV-1 T-cell line adapted strain MN was significantly 
higher in patients with successful HAART therapy compared to patients who were 
failing therapy, however MN neutralizing antibody titers decreased in treatment 
successes over time whereas the titers remained stable during the same time 
period in treatment failures. Interestingly, when neutralizing antibody titers were 
evaluated against clinical subtype B isolates, a different neutralization pattern was 
observed. Before HAART was initiated, neutralizing antibody titers were higher in 
treatment successes than treatment failures. One year after HAART initiation, the 
treatment successes showed a decrease in cross neutralizing antibody titers. By 
contrast HAART failures exhibited more cross reactive neutralizing antibodies after 
1 year of HAART (Morris, Katzenstein et al. 2001). Overall, neutralizing antibody 
titers and breadth was greater in patients failing therapy compared to patients with 
successful therapy. This study suggests that the suppression of viremia as a result 
of successful HAART therapy correlates with a decreased humoral response; this 
may be due to decreased antigen exposure and stimulation (Morris, Katzenstein et 
al. 2001). This is consistent with the data from our study where 50% of the 
samples within the DR cohort show potent neutralization breadth and 40% of the 
samples exhibited cross reactive neutralizing antibodies.  
 
Overall, treatment experienced patients failing their first line therapy regimens 
harbour increased neutralization levels compared to treatment naive patients. This 
is consistent with the findings of Morris et al (Morris, Katzenstein et al. 2001). The 
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observed increase in neutralization capacity of treatment experienced patients 
may however be due to the suppression of viral loads during therapy, allowing 
time for the partial recovery of the humoral immune system, therefore once viral 
loads increase again in treatment failures, the immune system is able to mount a 
potent humoral response against the virus (Bailey, Lassen et al. 2006). However, 
longitudinal studies would need to be performed to make a direct comparison of 
the neutralizing antibody responses in patients before and during or after HAART.  
 
4.6 JM Cohort 
 
The 2 broadly neutralizing antibodies, 2F5 and 4E10 which show reactivity to the 
host phospholipid, cardiolipin also share similar structural features to antibodies 
produced in autoimmune disease patients (Haynes, Moody et al. 2005). This could 
provide a possible reason for why they are so rarely produced in infected 
individuals due to B-cell tolerance mechanisms preventing their production 
(Verkoczy, Diaz et al.). Molecular mimicry may play a vital role in the auto reactive 
nature of these antibodies. For example, the HIV-1 V3 loop shares homology with 
a conserved part of the T-cell receptor (Lake, Schluter et al. 1994). Similarly the 
gp41 region of the HIV-1 envelope shares homology with a conserved domain of 
the MHC class II molecule (Golding, Robey et al. 1988; Fraziano, Montesano et al. 
1996). Interestingly, the C5 region of gp120 also shows homology with host MHC 
class I and class II molecules (Cadogan, Austen et al. 2008).  
 
To evaluate the presence of HIV-1 specific neutralizing antibodies among 
individuals with autoimmune diseases, we screened the serum of 10 HIV-1 
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seropositive or seronegative participants with autoimmune disorders. Our results 
revealed 3 serum samples TN5, TN6 and TN8 that showed greater than average 
neutralization breadths against a panel of 5 subtype C and 1 subtype B Env-
pseudoviruses. Further analysis and characterization studies are required to map 
the neutralizing epitopes of these antibodies and determine if 2F5 or 4E10-like 
antibodies are present in the serum of these individuals. All 3 serum samples were 
isolated from HIV-1 seropositive individuals.  
 
Participant TN6 had a CD4 count of 101 cells/µl; however, the viral load was not 
available. This patient also presented with the autoimmune disorders, rheumatoid 
arthritis and bicytopenia. Rheumatoid arthritis is a systemic autoimmune disorder 
disease affecting the synovial tissues. Interestingly it has been found that the 
chemokine receptor, CCR5 plays a major role in disease progression of 
rheumatoid arthritis (Gómez-Reino, Pablos et al. 1999). Participant TN5 had a 
CD4 count of 250 cells/µl and presented with pancytopenia and TN8 was isolated 
from an HIV-1 infected individual with a CD4 counts of 255 cells/µl and an 
undetectable viral load while TN10 was isolated from a patient who presented with 
antiphospholipid syndrome (APS) as well as cytopenias. This participant had a 
very low CD4 count of 55 cells/µl and a viral load of 35 000 RNA copies/ml. APS is 
characterized by the production of auto antibodies against phospholipids such as 
cardiolipin and β2-glycoprotein I, also known as apolipoprotein H (Rand 2007). 
APS is often seen in conjunction with other autoimmune disorders such as 
Immune Thrombocytopenia Purpura (ITP) which is characterized by platelet 
destruction and impaired platelet production.  
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Serum samples TN2 and TN9 are of great interest since they were only able to 
neutralize the subtype B pseudovirus, B11 but none of the subtype C 
pseudoviruses. This suggests that these subjects harbour neutralizing antibodies 
which recognize subtype B viruses better than subtype C viruses. These may 
include 447-52D-like antibodies or 2G12-like antibodies which recognize epitopes 
that are better exposed on subtype B viruses than subtype C viruses. As 
mentioned previously, 447-52D recognizes the GPGR motif present on the V3 
loop of subtype B viral isolates and 2G12 neutralization is dependent on glycans at 
positions 295, 339 and 386 however the glycan at position 295 is not present in 
the majority of subtype C isolates (Binley, Wrin et al. 2004). 2F5 also exhibits 
better neutralization against subtype B isolates compared to subtype B because 
the minimum requirement epitope (DKW) is substituted with DSW in most subtype 
C viruses (Purtscher, Trkola et al. 1996; Stiegler, Kunert et al. 2001).  
 
Clinical data showed that TN2 was HIV-1 seropositive and presented with 
thrombocytopenia and TN9 was HIV-1 seropositive with bicytopenia. Interestingly, 
all the serum samples with greater than average neutralizing antibody activity 
showed presented with cytopenias, (pancytopenia, bicytopenia or 
thrombocytopenia). Cytopenia refers to the reduction in the number of blood cells 
(Pizzo PA. 1999). Thrombocytopenia refers to the destruction of platelets whereas 
bicytopenia is characterized by the depressed bone marrow production of 2 cell 
lines and pancytopenia is characterized by the reduction in erythrocytes, 
leukocytes and platelets (Pizzo PA. 1999).  
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A study by Rawson et al (2007) showed that chronic infection with HIV-1 also 
results in the production of autoreactive CD8+ T-cells that present a set of self-
peptides on MHC class 1 that have escaped thymic tolerance. This is suggestive 
that HIV-1 exposure results in the breaking of tolerance mechanisms in the host 
making it susceptible to cellular and humoral autoreactivity. It has also been 
documented that HIV-1 infection causes severe damage to memory B-cells 
responsible for antibody production (Cagigi, Nilsson et al. 2008). These findings 
provide possible explanations for the elicitation of cross reactive neutralizing 
antibodies with auto reactivity in HIV-1 infected patients.  
 
Bone marrow samples were collected from 8 out of the 10 participants for future 
studies of participant samples with exceptionally broad neutralizing antibody 
activity. RNA would be isolated from the bone marrow of these samples and used 
to generate an antibody phage display library in an attempt to generate 
monoclonal antibodies with broadly neutralizing activity against diverse viral 
isolates.    
 
4.7. Concluding remarks 
 
In this study we evaluated the presence of neutralizing antibodies in patients with 
HIV-1 infection with slow disease progression, HIV-1 subtype C chronically 
infected treatment naive patients, HIV-1 subtype C infected treatment experienced 
patients failing first line therapy and HIV-1 seropositive or seronegative 
participants with autoimmune diseases. All samples were screened against a 
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panel of 6 generated pseudoviruses comprising 5 subtype C and 1 subtype B Env-
pseudoviruses.  
 
No correlation was observed between the presence of neutralizing antibodies and 
slow disease progression within the CT cohort. In addition, subjects who had 
progressed to AIDS in the absence of antiretroviral therapy showed similar 
neutralizing antibody levels to the slow progressors. These results suggest that the 
delayed progression observed in the 9 slow progressor participants is not due to 
the presence of neutralizing antibodies. Further analysis into the participants’ 
genetics and cellular immune responses are required for the characterization of 
slow progression in these individuals (these studies are currently underway in the 
Tiemessen laboratory). Although the DR cohort showed high neutralizing antibody 
titers, our assay could not confirm that it was due to neutralizing antibodies and 
not antiretroviral drugs. To confirm that the measured neutralization of these 
samples are due to neutralizing antibodies, future studies are required and should 
include HIV-1 negative controls with the addition of the predicted ARV drug levels 
or the removal of drugs before the assay via dialysis, or the purification of antibody 
from the plasma samples prior to the neutralization assays. The latter would be the 
most accurate measurement of the presence of neutralizing antibodies in these 
plasma samples (Dreyer, Kallas et al. 1999). Cross sectional analysis of 
neutralizing antibody responses before and during HAART reveal that treatment 
experienced patients failing first line therapy harbor increased neutralizing 
antibody titers compared to treatment naïve patients.  
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Within the JM cohort, 3 participants (TN5, TN6 and TN8) are worth investigating 
further against a larger panel of pseudoviruses representing diverse subtypes and 
the isolation of RNA may be required from bone marrow samples that were 
obtained from these patients during this study for the generation of monoclonal 
antibodies.  
 
In conclusion, this study has identified 6 individuals out of 40 with exceptionally 
broad neutralizing antibodies capable of neutralizing all 6 subtype C and B 
generated pseudoviruses used in this study. In addition, 5 individuals were 
identified that were able to neutralize at least 3 out of 6 generated pseudoviruses. 
Further characterization of the antibody responses in these individuals is 
necessary to provide useful insight into the specificities of broadly neutralizing 
antibody epitopes which may be useful for the generation of vaccine immunogens.   
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A.1 Ethics 
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A.2 Patient information leaflet 
 
 
Introduction 
Good day, we are from the Department of Molecular Medicine and Haematology at 
the University of the Witwatersrand Medical School. We are doing research on HIV 
to help us understand how to make a vaccine against this disease.  We would like 
to invite you to consider participating in a research study, entitled ‘Identification 
and characterization of HIV-1 specific neutralizing antibodies from HIV-1 
seropositive patients and autoimmune (HIV-1 seropositive or seronegative) 
participants.’ 
1. Before agreeing to participate, it is important that you read and understand 
the following explanation of the purpose of the study, the study procedures, 
benefits, risks, discomforts as well as the alternative procedures that are available 
to you as a study participant. 
2.  This information leaflet is to help you to decide if you would like to 
participate. You should fully understand what is involved before you agree to take 
part in this study.  
3. If you have any questions, do not hesitate to ask me.   
4. If you choose to participate in this study, you will be free to withdraw from 
the study any time without giving reasons for your withdrawal. This will not affect 
your right to future care at the hospital. 
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5. If you choose to participate in this study, you will be asked to sign this 
document to confirm that you understand the study. 
The following information describes the study and your role as a possible 
participant. We will answer any questions you may have about this information 
sheet and about the study.  Please read this information carefully and do not 
hesitate to ask any questions about the study information provided below. 
 
Why are we doing this study? 
The aim of this study is to investigate if you have certain special proteins called 
neutralizing antibodies against HIV. The reason we are interested in the 
neutralizing antibodies is that they will help us understand how the HI virus infects 
the body and how the body responds to the virus. These antibodies will also help 
us to develop vaccine against the HI virus. Currently there is no vaccine against 
the HI virus. 
 
Why are we interested in you as participant in this study? 
Your doctor has requested us to perform a procedure called bone marrow 
aspiration. This procedure is necessary for your doctor to be able to find out what 
is wrong with you. Bone marrow aspiration involves putting a needle into your 
bone space and sampling the content of the bone space called bone marrow. 
Bone marrow is then sent to the laboratory for analysis and for reporting.  
Whilst doing this procedure we would like to take an additional sample of bone 
marrow to be used for this research. The sample taken will be approximately a 
teaspoon (5ml) of bone marrow.  
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In addition to the bone marrow, we would like to request that you donate a 
tablespoon (10ml) of blood which will be taken from your arm vein. This blood and 
bone marrow samples will then be taken to laboratory for further analysis. 
 
What happens to your blood and bone marrow samples in the laboratory? 
The samples taken will be handled differently depending the nature of analysis to 
be done. Blood samples will be spun, separated, frozen and stored. They will then 
be analysed for neutralizing antibodies. Bone marrow samples will be spun, 
separated and also frozen.  The tests done on these samples will be only those 
outlined in this study. Consent will need to be obtained from the Human Research 
Ethics committee if there is a need to do other testing on the remaining samples. 
 
 
What are the risks and discomforts in this study? 
Blood sampling will be exactly the same as it done during your normal hospital 
visit. Drawing blood may result in fainting, dizziness, inflammation of the vein, 
pain, bruising, bleeding, or infection at the site of puncture.  The amount of blood 
taken is small and will therefore have negligible effects to your health. Bone 
marrow sampling is associated with pain. This pain is minimized by injecting local 
anaesthesia at the site of aspiration. Drawing bone marrow may result in fainting, 
dizziness, inflammation, pain, bruising, bleeding, or infection at the site of 
puncture. The pain is further minimized by giving you a pain tablet before and after 
the procedure. 
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What are the benefits of participating? 
You will not personally benefit from participating in this study. You will not be paid 
or compensated in any way for participating in the study.  
 
What if you do not want to participate in the study? 
You may choose not to participate in this study.  If you decide not to participate in 
this study, you will continue to receive your standard care in this hospital.  
 
 
How is confidentiality of the study information protected? 
All the information collected from you, including samples, will be identified with a 
number to ensure your identity will be kept confidential. Only the study doctors 
hold the information that allows the number to be linked to your name. 
 
The information collected will be processed, analyzed and reported by study 
doctors. The result will also be published in scientific articles. You will not be 
identified in person in any reports/publications. 
 
You have the right to ask to be shown what data about you has been collected and 
if you think anything is incorrect you may ask to have it corrected. 
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Representatives of the Ethics Committee staff may require access to your medical 
records to ensure the study is properly conducted and that the data collected is 
correct. Your privacy will be respected. 
 
Study-related Injury 
 If you suffer an injury or illness because of your direct participation in this 
research study, you will be given any medical treatment that is necessary to help 
you recover from the injury or illness.  
 
 
Whom to contact if needing further information on this study? 
Your study doctor or his/her delegate will answer any questions you may have.  
The 24-hour telephone number, through which you can reach your study doctor or 
another authorised person, is 083 644 5659. 
 
If you want any information regarding your rights as a research participant, or 
complaints regarding this research study, you may contact Prof. Cleaton-Jones, 
Chairperson of the University of the Witwatersrand, Human Research Ethics 
Committee (HREC), which is an independent committee established to help 
protect the rights of research participants at (011) 717 2301. 
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Voluntary Participation 
Your participation in this study is voluntary.  No study procedures will be 
performed until you have read, understood, and signed this informed consent 
form. You may refuse to participate or may discontinue participation at any time 
during the study without penalty or loss of benefits to which you are otherwise 
entitled.   
If you decide to participate in this study, you will be given a signed copy of this 
information sheet. 
 
Ethical Approval 
This study protocol has been submitted to the University of the Witwatersrand, 
Human Research Ethics Committee (HREC) and written approval has been 
granted by that committee.  
The study has been structured in accordance with the Declaration of Helsinki (last 
updated: September 2004), which deals with the recommendations guiding 
doctors in biomedical research involving human participants.  A copy may be 
obtained from your study doctor should you wish to review it. 
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A.3 Patient informed consent 
 
INFORMED CONSENT (FOR PARTICIPANTS 18 YEARS OR OLDER) 
 
 I have read this information sheet and my questions have been answered to       
my satisfaction.   
 I voluntarily consent to participate.   
 I understand that if I choose to not participate or to withdraw, my current 
medical care will not be affected by this decision. 
  I authorize the release of my medical records to the Authorized 
Representatives, as specified in this consent form. 
 By signing and dating this consent form, I have not waived any of the legal 
rights that I would have if I were not a participant in a research study. 
 
 
1. PARTICIPANT: 
 
Printed Name  Signature / Mark or Thumbprint    Date and Time           
 
2. STUDY DOCTOR/NURSE: 
 
Printed Name  Signature     Date and Time 
 
3. TRANSLATOR / OTHER PERSON EXPLAINING INFORMED 
CONSENT………………... (DESIGNATION): 
 
Printed Name  Signature           Date and Time 
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Appendix B 
 
B.1. Tissue culture reagents 
 
B.1.1 Complete RPMI-1640 
 
50 ml 10% heat inactivated foetal calf serum (FCS) (Gibco,USA), 5 ml L-glutamine 
(Gibco,USA) and 2.5 ml antibiotics (0.01mg/ml streptomycin and 100 units/ml 
penicillin) (Sigma-Aldrich) were added to 500 ml RPMI-1640 (Sigma-Aldrich) and 
mixed thoroughly before storage at 4°C until use.   
 
B.1.2 Freezing mix 
9 ml FCS (Gibco, USA) was added to 1 ml DMSO (Fluka, USA) and mixed 
thoroughly before use. 
 
B.1.3 Complete Dulbecco’s Modified Eagle Medium (DMEM) 
50 ml 10% heat inactivated FCS (Gibco, USA), 5 ml of 2mM L-glutamine and 2.5 
ml antibiotics (Sigma-Aldrich) (0.01mg/ml strep and 100 units/ml penicillin) were 
added to 500 ml DMEM (Sigma-Aldrich) and mixed thoroughly before storage at 
4°C until use. 
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Appendix C 
 
C.1. Solutions for bacterial cell culture 
 
C.1.1 LB Broth 
 
10g tryptone (Oxoid Inc; Hampshire, England), 5g yeast extract (Biolab; Gauteng, 
South Africa) and 10g NaCl (Sigma-Aldrich) were dissolved in 1 litre deionised 
water (Adcock Ingram). The broth was then autoclaved for 20 minutes on the liquid 
cycle (121ºC, 1kg/cm2, 20 minutes) and stored at room temperature until use. 
 
C.1.2. Transformation buffer 
 
1.4702 g CaCl2.2H2O (Merck), 0.3024g PIPES (Boehringer Mannheim; Germany) 
and 15 ml of autoclaved glycerol were made up to a final volume of 100 ml with 
distilled water (Adcock Ingram). The pH of the solution was adjusted to 7.0 with 
10M NaOH (Merck). The buffer was autoclaved on the liquid cycle (121ºC, 
1kg/cm2, 20 minutes) and stored at -20 ºC until use. 
 
C.1.3. Nutrient Agar Plates 
 
2g tryptone (Oxoid Inc; Hampshire, England), 1g yeast extract (Biolab; Gauteng, 
South Africa), 2g NaCl (Sigma-Aldrich) and 3g agar powder (Sigma-Aldrich) were 
dissolved in 200 ml deionised water. The Agar was then autoclaved for 20 minutes 
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on the liquid cycle (121ºC, 1kg/cm2, 20 minutes) and stored at room temperature 
until use. The solution was allowed to cool before the addition of ampicillin 
(100mg/ml) (Roche) and poured into 90 mm Petri dishes and allowed to set. 
 
C.1.4 Ampicillin (100mg/ml) 
 
1g Ampicillin (Roche) was dissolved in 10 ml of 70% ethanol and stored in 1 ml 
aliquots at -20°C until used. 
  
C.1.5 Composition of buffers for large scale plasmid preparations, taken 
from Qiagen Plasmid Purification Handbook (Qiagen)  
 
C.1.5.1 Buffer P1 (Qiagen formulation) 
 
6.06g Tris base and 3.72g Na2EDTA.2H2O were dissolved in 800 ml distilled water 
and the pH was adjusted to 8.0 with HCl. The total volume was adjusted to 1litre 
with distilled water and 100mg RNase A was added per litre of P1. The solution 
was stored at 4°C after the addition of RNase A. 
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C.1.5.2 Buffer P2 (Qiagen formulation) 
 
8.0g of NaOH pellets was dissolved in 950 ml distilled water and 50 ml 20% SDS 
(w/v) was added to a final volume of 1 litre. 
 
C.1.5.3 Buffer P3 (Qiagen formulation) 
 
294.5g potassium acetate was dissolved in 500 ml distilled water. The pH was 
adjusted to 5.5 with glacial acetic acid (~110 ml). The volume was adjusted to 
1litre with distilled water. 
 
C.1.5.4 Buffer QBT (Qiagen formulation) 
 
43.83g NaCl and 10.46g MOPS (free acid) were dissolved in 800 ml distilled 
water. The pH was adjusted to 7.0 with NaOH. 150 ml pure isopropanol and 15 ml 
10%Tirton X-100 solution was added to the mixture and the volume was adjusted 
to 1 litre with distilled water.  
 
C.1.5.5 Buffer QC (Qiagen formulation) 
 
58.44g NaCl together with 10.45g MOPS (free acid) were dissolved in 800 ml 
distilled water. The pH was adjusted to 7.0 with NaOH. 150 ml pure isopropanol 
was added and the volume was adjusted to 1litre with distilled water. 
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C.1.5.6 Buffer QF (Qiagen formulation) 
 
73.05g NaCl 6.06g Tris base were dissolved in 800 ml distilled water and the pH 
was adjusted to 8.5 with HCl. 150 ml pure isopropanol was added and the total 
volume was adjusted to 1 litre with distilled water.  
 
C.2. Solutions for agarose gel electrophoresis  
 
C.2.1 50 X Tris acetate EDTA (TAE) Buffer 
 
242g of Tris base, 57.1 ml of glacial acetic acid and 100 ml of 0.5M EDTA were 
mixed with distilled water to a final volume of 1L and stored at room temperature 
until use.  The solution was diluted to 1X TAE by mixing 20 ml of 50X TAE with 
980 ml of distilled water. 
 
C.2.2 6X DNA Loading Buffer 
 
0.25% Bromophenol Blue (Saarchem; Merck Chemicals, Gauteng, South Africa) 
and 30% glycerol were made up in 10 ml of dH2O. The buffer was stored in 1 ml 
aliquots at -20oC until required. 
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C.2.3 1% Agarose gel 
 
1g agarose powder (Sigma-Aldrich) was added to 100 ml of 1XTris acetate EDTA 
(TAE) buffer and heated in a microwave until the agarose completely dissolves. 
The solution was then allowed to cool at room temperature before the addition of 
7.5µl Ethidium Bromide (0.5μg/ml). (Promega, USA). The agarose was then 
poured and allowed to set in a Bio-Rad Gel Chamber System (Bio-Rad). 
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